US20140378454A1 - Novel methods - Google Patents

Novel methods Download PDF

Info

Publication number
US20140378454A1
US20140378454A1 US14/371,843 US201314371843A US2014378454A1 US 20140378454 A1 US20140378454 A1 US 20140378454A1 US 201314371843 A US201314371843 A US 201314371843A US 2014378454 A1 US2014378454 A1 US 2014378454A1
Authority
US
United States
Prior art keywords
hybrid nanoparticles
raw
matrix
soluplus
hcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/371,843
Other languages
English (en)
Inventor
Magnus Brisander
Mustafa Demirbüker
Gérald Jesson
Martin Malmsten
Helene Dérand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XSpray Microparticles AB
Original Assignee
XSpray Microparticles AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XSpray Microparticles AB filed Critical XSpray Microparticles AB
Priority to US14/371,843 priority Critical patent/US20140378454A1/en
Assigned to XSPRAY MICROPARTICLES AB reassignment XSPRAY MICROPARTICLES AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DERAND, HELENE, MALMSTEN, MARTIN, BRISANDER, MAGNUS, DEMIRBUKER, MUSTAFA, JESSON, GERALD
Publication of US20140378454A1 publication Critical patent/US20140378454A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to the field of methods for providing components of pharmaceutical compositions comprising poorly water-soluble drugs.
  • the present invention relates to methods for providing hybrid nanoparticles of protein kinase inhibitors (PKIs), in order to increase the dissolution rate and resulting bioavailability of said PKIs, useful in pharmaceutical compositions.
  • PKIs protein kinase inhibitors
  • Components of cellular signal transduction pathways that regulate the growth and differentiation of normal cells can, when dysregulated, lead to the development of cellular proliferative disorders and cancer. Mutations in cellular signaling proteins may cause such proteins to become expressed or activated at inappropriate levels or at inappropriate times during the cell cycle, which in turn may lead to uncontrolled cellular growth or changes in cell-cell attachment properties.
  • Protein kinases are kinase enzymes that modify proteins by chemically adding phosphate groups (phosphorylation). Phosphorylation usually results in a functional change of the target protein by changing enzyme activity, cellular location, or association with other proteins. Protein kinases can be subdivided or characterised by the amino acids of the target protein whose phosphorylation they control: most kinases act on both serine and threonine, the tyrosine kinases act on tyrosine, and a number (dual-specificity kinases) act on all three.
  • protein kinases that phosphorylate other amino acids, including histidine kinases that phosphorylate histidine residues.
  • the human genome contains about 500 protein kinase genes and up to 30% of all human proteins may be modified by protein kinases.
  • Kinases are known to regulate the majority of cellular pathways, especially those involved in signal transduction. Dysregulation of protein kinases by mutation, gene rearrangement, gene amplification, and overexpression of both receptor and ligand has been implicated in the development and progression of human cancers.
  • Protein kinase inhibiting compounds or protein kinase inhibitors (PKIs) are therefore useful for treating diseases caused by or exacerbated by overexpression or upregulation of protein kinases.
  • TKIs tyrosine kinase inhibitors
  • tyrphostins tyrosine kinase inhibitors
  • a major objective of formulation chemistry is to improve drug efficiency and safety, by e.g. improving bioavailability and stability as well as convenience to the patient.
  • Bioavailability means the rate and extent to which an active substance or therapeutic is absorbed from a pharmaceutical form and becomes available at the site of action.
  • the most common and preferred method of delivery due to convenience, ease of ingestion, and high patient compliance to treatment is the oral route of drug delivery.
  • drug absorption from the gastrointestinal tract is limited by poor aqueous solubility and/or poor membrane permeability of the drug molecules.
  • PKIs are generally weak bases that dissolve only slightly at low pH (e.g. 100-1000 mg/L) and are practically insoluble at neutral pH (e.g. 0.1-10 mg/L). Therefore, enhancing the solubility and dissolution rate of PKI-based drugs is important for improving the bioavailabitity and efficacy of most of these drugs.
  • Typical PKIs exhibit non-polypetide structure and have relatively low molecular weights, such as ⁇ 10000 dalton or ⁇ 5000 dalton.
  • pH-dependent solubility is a well-known issue for many oral formulations of poorly water-soluble substances, such as PKIs, since most of the absorption of the drug occurs in the small and large intestine, where pH is close to neutral. There is thus a continuing need to develop and improve the dissolution characteristics of oral solid dosage forms of PKI-based drugs.
  • PKI-based drugs Budha N R, Frymoyer A, Smelick G S, Jin J Y, Yago M R, Dresser M J, Holden S N, Benet L Z, Ware J A. Clin Pharmacol Ther. 2012 August; 92(2):203-13. Therefore, methods for improving dissolution of PKI-based drugs, as well as of other poorly water-soluble drugs, at neutral (intestinal) pH are highly desirable.
  • US20090203709 discloses a pharmaceutical dosage form comprising a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer and at least one pharmaceutically acceptable solubilizer. Further the reference discloses methods for preparing the above-mentioned pharmaceutical dosage form, comprising preparing the homogenous melt of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer and at least one pharmaceutically acceptable solubilizer, and allowing the melt to solidify to obtain a solid dispersion product.
  • EP2105130 discloses pharmaceutical formulations comprising a solid dispersion or solid solution, containing a polymer and an active agent in amorphous form. Further, the formulation comprises an external polymer to stabilize the solution, such that the % by weight of the external polymer is less than 20% of the total weight of the pharmaceutical formulation. Additionally, the reference discloses a hot melt extrusion method for production of the above-mentioned formulation.
  • the present invention relates to methods of producing stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component.
  • one or more solubilizers may be added to the particles, present separately from the particles, or within the particles.
  • FIG. 1 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles comprising nilotinib HCl produced by the methods of the invention. Further experimentation with both nilotinib base and nilotinib HCl is found in Example 1. The details of the particles are described in Example 1, Table 1, for experiment 3, 30 and 37, respectively. Briefly, experiment 30 represents hybrid nanoparticles comprising nilotinib HCl and HPMCP HP55 and wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer is present separately from the hybrid nanoparticles.
  • Experiment 3 represents raw, crystalline nilotinib HCl and experiment 37 represents hybrid nanoparticles of nilotinib HCl, HPMCP HP55 and the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer, present within the hybrid nanoparticles.
  • the experiments illustrated in the graphs were carried out at pH 6.5, in FaSSIF.
  • FIG. 2 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles comprising erlotinib produced by the methods of the invention. Further experimentation with erlotinib is found in Example 2. The details of the hybrid nanoparticles are described in Example 2, Table 7, for experiment 58, 65 and 67, respectively. Briefly, experiment 65 represents hybrid nanoparticles with erlotinib HCl and HPMC-AS, wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer is present separately from the hybrid nanoparticles.
  • Experiment 58 represents raw, crystalline erlotinib HCl and experiment 67 represents hybrid nanoparticles of erlotinib HCl, HPMC-AS and the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer present within the hybrid nanoparticles.
  • the experiments illustrated in the graphs were carried out at pH 6.5 in FaSSIF.
  • FIG. 3 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles comprising pazopanib produced by the methods of the invention. Further experimentation with pazopanib is found in Example 3. The details of the hybrid nanoparticles are described in Example 3, Table 13, for experiment 84, 91 and 93, respectively.
  • experiment 91 represents hybrid nanoparticles comprising pazopanib and PVP 90K and wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer is present separately from the hybrid nanoparticles
  • experiment 93 represents hybrid nanoparticles comprising pazopanib, PVP 90K and the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer, present within the hybrid nanoparticles.
  • Experiment 84 represents raw, crystalline pazopanib. The experiments illustrated in the graphs were carried out at pH 6.5, in FaSSIF.
  • FIG. 4 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles comprising lapatinib base produced by the methods of the invention. Further experimentation with both lapatinib base and lapatinib ditosylate salt is found in Example 4. The details of the hybrid nanoparticles are described in Example 4, Table 19, for experiment 110, 122 and 126, respectively. Briefly, experiment 122 represents hybrid nanoparticles comprising lapatinib base and HPC EF, wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer is present separately from the hybrid nanoparticles.
  • Experiment 110 represents raw, lapatinib base and experiment 126 represents hybrid nanoparticles of lapatinib base, HPC LF and the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer present within the hybrid nanoparticles.
  • the experiments illustrated in the graphs were carried out at pH 6.5 in FaSSIF.
  • FIG. 5 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles particles comprising nilotinib produced by the methods of the invention.
  • the details of the hybrid nanoparticles are described in Example 5, Table 21, for experiment 127, 128 and 129, respectively.
  • experiment 129 represents a physical mixture of raw, crystalline nilotinib HCl, HPMCP HP55 and the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer.
  • Experiment 128 represents hybrid nanoparticles comprising nilotinib HCl and HPMCP HP55, wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer is present separately from the hybrid nanoparticles.
  • Experiment 127 represents hybrid nanoparticles of nilotinib HCl and HPMCP HP55. The experiments illustrated in the graphs were carried out at pH 1.4 in SGF.
  • FIG. 6 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles comprising gefitinib produced by the methods of the invention. Further experimentation with gefitinib is found in Example 6. The details of the compositions are described in Example 6, Table 22, for experiment 131, 133, 135 and 137, respectively. Briefly, experiment 131 represents raw, crystalline gefitinib. Experiment 133 represents a mixture of raw, crystalline gefitinib, HPMCP HP55 and the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer. Experiment 135 represents hybrid nanoparticles of gefitinib and HPMCP HP55.
  • Experiment 137 represents hybrid nanoparticles of gefitinib and HPMCP HP55 wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer is present separately from the hybrid nanoparticles.
  • the experiments illustrated in the graphs were carried out at pH 6.5 in FaSSIF.
  • FIG. 7 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles comprising dasatinib produced by the methods of the invention.
  • the details of the hybrid nanoparticles are described in Example 7, Table 24, for experiments 138-141. Briefly, experiment 138 represents raw, crystalline dasatinib.
  • Experiment 139 represents a mixture of raw, crystalline dasatinib, Kollidon VA64 and the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer.
  • Experiment 140 represents hybrid nanoparticles of dasatinib and Kollidon VA64.
  • Experiment 141 represents hybrid nanoparticles of dasatinib and Kollidon VA64 wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer is present separately from the hybrid nanoparticles.
  • the experiments illustrated in the graphs were carried out at pH 6.5 in FaSSIF.
  • FIG. 8 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles comprising sorafenib produced by the methods of the invention.
  • the details of the hybrid nanoparticles are described in Example 8, Table 26, for experiments 142-145.
  • experiment 142 represents raw, crystalline sorafenib tosylate.
  • Experiment 143 represents a mixture of raw, crystalline sorafenib tosylate, HPMCP HP55 and the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer.
  • Experiment 144 represents hybrid nanoparticles of sorafenib tosylate and HPMCP HP55.
  • Experiment 145 represents hybrid nanoparticles of sorafenib tosylate and HPMCP HP55 wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer is present separately from the hybrid nanoparticles.
  • the experiments illustrated in the graphs were carried out at pH 6.5 in FaSSIF.
  • FIG. 9 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles comprising crizotinib produced by the methods of the invention. Further experimentation with crizotinib is found in Example 10. The details of the compositions are described in Example 10, Table 30, for experiment 150, 152, 153 and 156, respectively. Briefly, experiment 150 represents raw, crystalline crizotinib. Experiment 152 represents a mixture of raw, crystalline crizotinib, PVP 30K and the solubilizer Cremophor RH40. Experiment 153 represents hybrid nanoparticles of crizotinib and PVP 30K.
  • Experiment 156 represents hybrid nanoparticles of crizotinib and PVP 30K wherein the solubilizer Cremophor RH40 is present separately from the hybrid nanoparticles.
  • the experiments illustrated in the graphs were carried out at pH 6.5 in FaSSIF.
  • FIG. 10 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles comprising axitinib produced by the methods of the invention. Further experimentation with axitinib is found in Example 11. The details of the compositions are described in Example 11, Table 32, for experiment 157, 158, 160 and 162, respectively. Briefly, experiment 157 represents raw, crystalline axitinib. Experiment 158 represents a mixture of raw, crystalline axitinib, Kollidon VA64 and the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer. Experiment 160 represents hybrid nanoparticles of axitinib and Kollidon VA64.
  • Experiment 162 represents hybrid nanoparticles of axitinib and Kollidon VA64 wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer is present separately from the hybrid nanoparticles.
  • the experiments illustrated in the graphs were carried out at pH 6.5 in FaSSIF.
  • FIG. 11 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles comprising vemurafenib produced by the methods of the invention. Further experimentation with vemurafenib is found in Example 12. The details of the compositions are described in Example 12, Table 34, for experiment 164, 166, 168 and 170, respectively. Briefly, experiment 164 represents raw, crystalline vemurafenib. Experiment 166 represents a mixture of raw, crystalline vemurafenib, CAP and the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer.
  • Experiment 168 represents hybrid nanoparticles of vemurafenib and CAP.
  • Experiment 170 represents hybrid nanoparticles of vemurafenib and CAP wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer is present separately from the hybrid nanoparticles.
  • the experiments illustrated in the graphs were carried out at pH 6.5 in FaSSIF.
  • FIG. 12 provides a graph showing the dissolution rate for stable, amorphous hybrid nanoparticles comprising nilotinib base produced by the methods of the invention, measured under sink conditions. Details are found in Examples 13 and 13.1, and Table 36 for experiments 500 and 501. Briefly, experiment 500 represents raw, nilotinib HCl. Experiment 501 represents hybrid nanoparticles of nilotinib base and HPMCP HP55. The experiments illustrated in the graphs were carried out at pH 6.5 in FaSSIF.
  • FIG. 13 provides a graph showing the dissolution rate for stable, amorphous hybrid nanoparticles comprising erlotinib HCl produced by the methods of the invention, measured under sink conditions. Details are found in Examples 13 and 13.2, Table 37 for experiments 510 and 511. Briefly, experiment 510 represents raw, erlotinib HCl. Experiment 511 represents hybrid nanoparticles of erlotinib HCl and HPMC AS.
  • FIG. 14 provides a graph showing the dissolution rate for stable, amorphous hybrid nanoparticles comprising pazopanib HCl produced by the methods of the invention, measured under sink conditions. Details are found in Examples 13 and 13.3, Table 38 for experiments 520 and 521. Briefly, experiment 520 represents raw, pazopanib HCl. Experiment 521 represents hybrid nanoparticles of pazopanib HCl and PVP90K.
  • FIG. 15 provides a graph showing the dissolution rate for stable, amorphous hybrid nanoparticles comprising lapatinib base produced by the methods of the invention, measured under sink conditions. Details are found in Examples 13 and 13.4, Table 39 for experiments 530 and 531. Briefly, experiment 530 represents raw, lapatinib ditosylate. Experiment 531 represents hybrid nanoparticles of lapatinib base and HPC If.
  • FIG. 16 provides a graph showing the dissolution rate for stable, amorphous hybrid nanoparticles comprising gefitinib produced by the methods of the invention, measured under sink conditions. Details are found in Examples 13 and 13.5, Table 40 for experiments 540 and 541. Briefly, experiment 540 represents raw, gefitinib. Experiment 541 represents hybrid nanoparticles of gefitinib and HPMCP HP55.
  • FIG. 17 provides a graph showing the dissolution rate for stable, amorphous hybrid nanoparticles comprising dasatinib produced by the methods of the invention, measured under sink conditions. Details are found in Examples 13 and 13.6, Table 41 for experiments 550 and 551. Briefly, experiment 550 represents raw, dasatinib. Experiment 551 represents hybrid nanoparticles of dasatinib and Kollidon VA64.
  • FIG. 18 provides a graph showing the dissolution rate for stable, amorphous hybrid nanoparticles comprising sorafenib tosylate produced by the methods of the invention, measured under sink conditions. Details are found in Examples 13 and 13.7, Table 42 for experiments 560 and 561. Briefly, experiment 560 represents raw, sorafenib tosylate. Experiment 561 represents hybrid nanoparticles of sorafenib tosylate and HPMCP HP55.
  • FIG. 19 provides a graph showing the dissolution rate for stable, amorphous hybrid nanoparticles comprising crizotinib produced by the methods of the invention, measured under sink conditions. Details are found in Examples 13 and 13.8, Table 43 for experiments 570 and 571. Briefly, experiment 570 represents raw, crizotinib. Experiment 571 represents hybrid nanoparticles of crizotinib and PVP 30K.
  • FIG. 20 provides a graph showing the dissolution rate for stable, amorphous hybrid nanoparticles comprising axitinib produced by the methods of the invention, measured under sink conditions. Details are found in Examples 13 and 13. 9, Table 44 for experiments 580, 581 and 582. Briefly, experiment 580 represents raw, axitinib. Experiment 581 represents hybrid nanoparticles of axitinib and Kollidon VA64 and experiment 582 represents hybrid nanoparticles of axitinib and HPMC AS.
  • FIG. 21 provides a graph showing the dissolution rate for stable, amorphous hybrid nanoparticles comprising vemurafenib produced by the methods of the invention, measured under sink conditions. Details are found in Examples 13 and 13.10, Table 45 for experiments 590, 591 and 592. Briefly, experiment 590 represents raw, vemurafenib. Experiment 591 represents hybrid nanoparticles of vemurafenib and Kollidon VA64 and experiment 592 represents hybrid nanoparticles of vemurafenib and CAP.
  • FIG. 22 provides graphs showing in vivo measurement of plasma levels after oral administration to beagle dogs of compositions, represented by formulations comprising stable, amorphous hybrid nanoparticles of nilotinib base and the polymeric stabilizing and matrix-forming components PVAP and HPMCP HP55, respectively (I/P), denoted PVAP and HP55, as well as wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer was added (I/P+S), denoted HP55s and PVAPs, respectively.
  • the experiments were carried out in beagle dogs pre-treated to have neutral stomach content.
  • Example 9 The hybrid nanoparticles are further described in experiments 146 and 147 (Example 9) and details of the in vivo experiments are set out in Example 14.
  • the experiments used a marketed formulation comprising nilotinib HCl (“Tasigna”) as reference.
  • FIG. 23 provides graphs showing in vivo measurement of plasma levels after oral administration to beagle dogs of compositions, represented by formulations comprising stable, amorphous hybrid nanoparticles of nilotinib base and the polymeric stabilizing and matrix-forming components PVAP and HPMCP HP55, respectively (I/P), denoted PVAP and HP55, produced by the methods of the invention as well as wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer was added (I/P+S), denoted PVAPs and HP55s, respectively.
  • the experiments were carried out in beagle dogs pre-treated to have acidic stomach content.
  • Example 9 The hybrid nanoparticles are further described in experiments 146 and 147 (Example 9) and details of the in vivo experiments are set out in Example 14.
  • the experiments used a marketed formulation comprising nilotinib HCl (“Tasigna”) as reference.
  • FIG. 24 provides graphs showing in vivo measurement of plasma levels after oral administration to beagle dogs of compositions, represented by formulations comprising stable, amorphous hybrid nanoparticles of nilotinib base and the polymeric stabilizing and matrix-forming components PVAP and HPMCP HP55, respectively (I/P) produced by the methods of the invention, denoted PVAP and HP55, as well as wherein the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer was added after hybrid nanoparticle formation (I/P+S), denoted PVAPs and HP55s, respectively.
  • the experiments were carried out in beagle dogs pre-treated to have acidic or neutral stomach content.
  • the hybrid nanoparticles are further described in experiments 146 and 147 (Example 9) and details of the in vivo experiments are set out in Example 14.
  • FIG. 25 provides graphs showing in vivo measurement of plasma levels after oral administration to beagle dogs of compositions, represented by formulations comprising stable, amorphous hybrid nanoparticles of nilotinib base and the polymeric stabilizing and matrix-forming components PVAP and HPMCP HP55, respectively (I/P) produced by the methods of the invention, denoted PVAP and HP55.
  • the experiments were carried out in beagle dogs pre-treated to have acidic or neutral stomach content.
  • the hybrid nanoparticles are further described in experiments 146 and 147 (Example 9) and details of the in vivo experiments are set out in Example 14.
  • FIG. 26 provides a graph showing the apparent solubility for stable, amorphous hybrid nanoparticles produced by the methods of the invention, before and after 11 months of storage at room temperature.
  • the experiment provides stable, amorphous hybrid nanoparticles comprising nilotinib base, HPMCP HP55 and the addition of the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer (I/P+S) as Exp 171 & Exp 172 with further details set out in Example 15.
  • FIG. 27 provides overlayed X-ray powder diffraction (XRPD) patterns of stable hybrid nanoparticles at 40% drug load, I/P nilotinib base/HPMCP HP55. Initial (top) and after 12 months storage at ambient temperature (bottom). The XRPD patterns are offset in order improve the visual comparison. Further details are set out in Example 15.
  • XRPD X-ray powder diffraction
  • hybrid nanoparticles refers to a group of particles, typically in the average size range of from 1 to 1000 nm, composed of at least two components, one of which is the PKI and the other a polymeric stabilizing and matrix-forming component.
  • the particles can be either crystalline or amorphous, or a mixture thereof.
  • the particles are “amorphous”, or “essentially amorphous”. This means that almost all, if not all, content of the particles comprise amorphous protein kinase inhibitor and polymeric stabilizing and matrix-forming component.
  • the level or degree of amorphicity is at least 60%, such as 70%, such as 80% or 85%, preferably at least 90% and more preferably >95%, wherein 100% represents that all material is amorphous in the particles.
  • Quantification of crystalline PKI or absence of crystalline PKI may be measured by X-ray powder diffraction methods as described in Saleki-Gerhardt A et al. Int J. Pharm. 1994; 101:237-247) or by water vapor sorption as described in Dash A K et al. J Pharm Sci. 2002 April; 91(4):983-90.
  • solid dispersion particles relates to “hybrid nanoparticles” as defined above, however, solid dispersion particles are typically larger or much larger in size (typically ⁇ m-mm, as described in Wu K. et al. J Pharm Sci. 2009 July; 98(7):2422-3).
  • the smaller size of hybrid nanoparticles contributes to further stabilizing the PKI against crystallization.
  • hybrid nanoparticles is in the average size range of from 1 to 1000 nm, such as below 500 nm, preferably below 250 nm.
  • stable refers to the level of stability of produced particles by the methods of the present invention and may be measured as the capability of the hybrid nanoparticles to remain in their physical state for 6-12 months storage at ambient temperature (e.g. 20-25° C.).
  • the level of stability may be measured by AUC measurements of dissolution rate over for instance 80 minutes of the particles, after such storage.
  • protein kinase inhibitor or “PKI” is meant a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.
  • PKIs include, but are not limited, to protein kinase inhibitors and tyrosine kinase inhibitors, such as axitinib, afatinib, bosutinib, crizotinib, cediranib, dasatinib, erlotinib, fostamatinib, gefitinib, imatinib, lapatinib, lenvatinib, lestaurtinib, motesanib, mubritinib, nilotinib, pazopanib, pegaptanib, ruxolitinib, sorafenib, semaxanib, sunitinib, tandunitib, tipifamib, vandetanib and vemurafenib; or salts or
  • polymeric stabilizing and matrix-forming component the component present in the hybrid nanoparticles together with the PKI.
  • said polymeric stabilizing and matrix-forming component exhibits a polymeric structure, such as, but not limited to, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. HPC ef, HPC If and HPC jf), hydroxypropyl methylcellulose (e.g. Methocel E3 and E15 and Pharmacoat), hydroxypropyl methylcellulose acetate succinate (HPMC AS), hydroxypropyl methylcellulose phthalate (e.g. HPMCP-HP55), polyvinylpyrrolidone (e.g.
  • PVAP polyvinyl acetate phthalate
  • copolyvidone e.g. Kollidon VA 64
  • crospovidon e.g. Kollidon CL
  • methacrylic acid and ethylacrylate copolymer e.g. Kollicoat ME
  • methacrylate acid and methyl methacrylate copolymer e.g. Eudragit L100
  • polyethylene glycol PEG
  • DL lactide/glycolide copolymer poly DL-lactide
  • CAP aminoalkyl methacrylate copolymers
  • Eudragit RL100, RL PO or RS PO carbomer homopolymer Type A (e.g. Carbopol 971P), carbomer homopolymer Type B (e.g. Carbopol 974P) and Poloxamers (e.g. Pluronics, Kolliphor).
  • carbomer homopolymer Type A e.g. Carbopol 971P
  • carbomer homopolymer Type B e.g. Carbopol 974P
  • Poloxamers e.g. Pluronics, Kolliphor
  • polymer or “polymeric” is here used to mean a compound that is made of monomers connected together to form a larger molecule.
  • a polymer generally consists of 20 or more monomers connected together, however less than 20 monomers connected together are here also referred to as polymers.
  • solubilizer is here used to mean a compound that increases the solubility of a substance, such as, but not limited to, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer (Soluplus), d- ⁇ -tocopherol acid polyethylene glycol 1000 succinate (TPGS), PEG-40 hydrogenated castor oil (Cremophor RH40), PEG-35 castor oil (Cremophor EL), PEG-40 stearate (MYRJ 540), hard fat (e.g. Gelucire 33/01), polyoxylglycerides (e.g. Gelucire 44/14), stearoyl polyoxylglycerides (e.g. Gelucire 50/13), PEG-8 caprylic/capric glycerides (e.g. Labrasol) and Poloxamers (e.g. Pluronics, Kolliphor).
  • TPGS polyvinyl caprolactam-polyvinyl a
  • the phrase “primary particles” refers to the smallest particulate entities formed during the precipitation process.
  • the boundaries of the particles are analyzed by SEM microscopy.
  • the primary particles may build together a more or less dense and porous network forming larger, agglomerated or bridging particles.
  • Parameters affecting the agglomeration are e.g. temperature that may modify the softness of the primary particles; ratio solvent/antisolvent affecting precipitation time, concentration of the PKI solution; and the nature of the polymeric stabilizing and matrix-forming agent(s).
  • the average size of the primary particles is typically between 1 to 1000 nm, preferably below 500 nm, more preferably below 250 nm.
  • the phrases “supercritical” and “supercritical fluid” refer to that a chemical substance that is set to both a temperature higher or equal than its critical temperature (Tc) and a pressure higher or equal than its critical pressure (Pc).
  • critical and critical fluid refer here to that one of critical temperature (Tc) or critical pressure (Pc) is set to a temperature or pressure higher than its critical temperature (Tc) or critical pressure (Pc), respectively, and the other of critical temperature (Tc) or critical pressure (Pc) is set to a temperature or pressure lower than its critical temperature (Tc) or critical pressure (Pc), respectively.
  • AUC area under the curve
  • Soluplus refers to polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer.
  • TPGS refers to d- ⁇ -tocopherol acid polyethylene glycol 1000 succinate.
  • Chremophor RH40 refers to PEG-40 hydrogenated castor oil.
  • PVAP refers to polyvinyl acetate phthalate.
  • PVP 90K refers to polyvinylpyrrolidone K-90.
  • PVP 30K refers to polyvinylpyrrolidone K-30.
  • HPMC-AS refers to hydroxypropyl methylcellulose acetate succinate.
  • HPMCP HP55 refers to hydroxypropyl methyl cellulose phthalate.
  • HPC hydroxypropyl cellulose
  • Kerdon VA64 refers to copolyvidone.
  • CAP refers to cellulose acetate phthalate
  • the dissolution mediums used for purposes of testing hybrid nanoparticles produced by the methods of the present invention includes Fasted State Stimulated Intestinal Fluid, referred to as FaSSIF, Fed State Stimulated Intestinal Fluid, referred to as FeSSIF, and Simulated Gastric Fluid, referred to as SGF.
  • FaSSIF media is tailored to represent a fasting state and has a pH of about 6.5 as well as particular osmolaric properties.
  • FeSSIF media is tailored to represent a fed state and has a pH of about 5 as well as specific osmolaric properties.
  • SGF is tailored to represent gastric fluid and has a pH of about 1.4 as well as particular osmolaric properties.
  • FaSSIF, FeSSIF and SGF media are generally used in in vitro models for dissolution of poorly water-soluble drugs.
  • the choice of medium will be dependent of the where in the intestinal tract and under what conditions (fasted or fed) particles are desired to dissolve and be taken up. Further details regarding these fluids are described in e.g. Hervé J. et al. Pharm Dev Technol. 2011 June; 16(3):278-86 and Jantratid, E., and Dressman, J. Dissolut. Technol. 2009 8, 21-25.
  • amorphous form non-crystalline solid form.
  • the ease of dissolution may at least in part be attributed to the amount of energy required for dissolution of the components from a crystalline or amorphous solid phase.
  • Amorphous particles require less energy for dissolution as compared to crystalline particles of the same compound.
  • the inventive methods produce hybrid nanoparticles comprising a PKI or a combination of two or more PKIs.
  • the particles may comprise a combination of one or more PKIs and at least one further active ingredient, such as one or more drugs.
  • Various kinds of PKIs can be effectively utilized.
  • PKIs protein kinase inhibitors
  • hydrates solvates (alcoholates) pharmaceutically acceptable acid salts, base salts or co-crystals of such protein kinase inhibiting compounds.
  • water-insoluble or poorly water soluble (or hydrophobic) compounds refers to compounds whose solubility in water at 25° C. is less than 1 g/100 ml, especially less than 0.1 g/100 ml in pure water at neutral pH.
  • the hybrid nanoparticles generated by the methods of the present invention are typically in the form of particles as described elsewhere in this specification.
  • There are a number of different methods for the formation of larger particles e.g. granulation, melt extrusion, spray drying, precipitation etc. all of which typically encompass starting with formation of a mixture between the Active Pharmaceutical Ingredient (API) and the polymeric stabilizing and matrix-forming component.
  • the inventive methods of the present invention are continous processes for generating hybrid nanoparticles. Continuous processes in this context means that particle formation is continuously ongoing while at the same time continuously withdrawing/collecting/retaining hybrid nanoparticles from the mixture after their formation. In the preferred methods, i.e.
  • the polymeric stabilizing and matrix-forming component may be present in either one or both of the two fluids depending on its solubility characteristics.
  • the mixing of the two fluids is taking place in a mixing function, e.g. a mixing chamber.
  • the mixing function typically is associated with a particle formation and separation function wherein the mixed fluid stream may pass through while retaining the hybrid nanoparticles.
  • Agents modifying the particle characteristics without being incorporated into the particles may be added to either one or both of the two fluids before the mixing step.
  • the fluids typically are conventional liquids or supercritical fluids, where supercritical fluids also include subcritical fluids (i.e. fluids for which only one of pressure and temperature is above its supercritical value).
  • Typical combinations are, a) conventional (i.e., non-supercritical) liquids for both the API solution and the antisolvent, b) supercritical solution of the API combined with conventional liquid for the antisolvent, c) conventional liquid for the API solution combined with supercritical fluid for the antisolvent, and d) supercitical fluids for both of the two fluids.
  • the antisolvent may be omitted.
  • a fluid stream, preferably supercritical, containing both the API and the polymeric stabilizing and matrix-forming component is then allowed to expand into the particle formation function. It is preferred that at least one of the fluids is in a supercritical state in the preciptiation methods described above. These kinds of precipitation methods are discussed in WO 2005061090 (Censdelivery AB), WO 2009072950 (XSpray Microparticles AB), WO 2009072953 (XSpray Microparticles AB), WO 2011159218 (XSpray Microparticles AB) and references cited in these publications.
  • solution encompasses that the solute is either a true solute or minute particles of colloidal dimensions (typically 1-1000 nm) and less than the particles to be produced.
  • a preferred particle formation system is the “Right Size system” developed by XSpray Microparticles AB, Sweden. A detailed description of the technology can be found in the WO-publications given in the preceding paragraph.
  • An important characteristic of the system is that the two fluid streams should merge within a nozzle at an angle in the interval 45°-135°, with preference for about 90° and sprayed into a particle formation/separation function.
  • the system allows for producing particles of predetermined size and/or morphology.
  • the Right Size system and apparatus will be described using the non-limiting example of a PKI as the drug and CO 2 as a supercrititcal fluid antisolvent.
  • the system consists of one pumping set-up for the PKI dissolved in a liquid solvent, referred to as the API solution, and one pumping set-up for an antisolvent, for example CO 2 , however also other antisolvents may be used when suitable.
  • Each pumping set-up includes instruments such as a flow meter and a pressure meter that are used to control the process conditions. These two pumping set-ups are fluidically connected at a spray nozzle.
  • a stream of liquid API solution is mixed with a stream of CO 2 under flow conditions within the spray nozzle.
  • the polymeric stabilizing and matrix-forming component is present in either the API solution or in the stream of CO 2 .
  • These streams are sprayed at the outlet of the nozzle into a precipitation vessel under controlled conditions (typically pressure and temperature).
  • CO 2 acts as an antisolvent and makes the API to precipitate together with the polymeric stabilizing and matrix-forming component into fine particles. Particles are retained in the vessel by a filtering set-up.
  • a back pressure regulator is typically used to control the pressure inside the precipitation vessel.
  • a pumping set-up control is set up for the modifier and the modifier is mixed with the CO 2 in a mixer before entering the nozzle.
  • the system operator When using the system, the system operator typically starts by equilibrating the system by pumping CO 2 , an “PKI like solution” (a solution similar in composition to the PKI solution but containing no PKI and no excipient) and the modifier (if used) through the system until flow rates, pressure and temperature have reached a desired steady state.
  • PKI solution composition PKI solution flow rate, CO 2 flow rate, CO 2 pressure and temperature, nature of the modifier and modifier flow rate, if such is used.
  • the “PKI like solution” is exchanged for the PKI solution and particles are produced and retained downstream of the mixing, e.g. downstream of the outlet of the nozzle.
  • the system is typically cleaned by pumping the “PKI like solution” through the system.
  • the particles are dried by flushing CO 2 through the retained particles in order to extract any remaining solvent.
  • the precipitation vessel is then depressurized and the particles can be collected.
  • the solution/solvent and the antisolvent are typically miscible with each other.
  • the pressure and temperature in the particle formation function, and/or upstream of this function, such as in the mixing function, provide supercritical or subcritical conditions in relation to the antisolvent.
  • the concentration of the PKI in the solution is typically below its saturation concentration, such as ⁇ 50%, such as ⁇ 60%, such as ⁇ 75%, such as ⁇ 85% or such as ⁇ 95% of the saturation concentration. Suitable concentrations are typically found in the interval ⁇ 20%, such as ⁇ 10% or ⁇ 5% or ⁇ 3% with lower limits being ⁇ 005% or 0.1% (all in w/v-%).
  • volatile for solvents typically means boiling points of ⁇ 200° C., such as ⁇ 150° C. or ⁇ 100° C., at atmospheric pressure. Examples are inorganic solvents and organic solvents with particular emphasis of dimethyl sulfoxide and trifluoroethanol and mixtures thereof. The term solvent includes mixtures of liquids which are miscible with each other.
  • the solutions may contain agents that enhance or diminish the solubility of the PKI, e.g. acidic, alkaline, buffer components and/or other organic solvents.
  • Illustrative fluids which can be used as an antisolvent are:
  • the antisolvent is typically selected for its ability to be readily dispersed into small droplets and for its ability to act as an atomizing agent and antisolvent against the PKI present in the solution.
  • Pc stands for critical pressure and Tc for critical temperature.
  • Compounds according to group (b) are typically selected amongst conventional liquids of the same general types as discussed for solvents above but with the difference that the PKI present in the solution must be poorly soluble in the antisolvent.
  • Particular liquids of group (b) comprise methanol, ethanol, acetone water and mixtures containing one or more of these fluids.
  • the antisolvents of group (a) above are typically used at pressures and temperatures providing i) supercritical conditions (supercritical fluid) or ii) a subcritical conditions (subcritical fluid) in the particle formation function and/or upstream of this function, such as in the mixing function and upstream of this latter function.
  • Variant (i) means pressures and temperatures which are typically above the critical pressure Pc and critical temperature Tc of the antisolvent used.
  • this typically means pressures in the interval (1.0-7.0) ⁇ Pc or in the interval ⁇ 10 bar, suitably ⁇ 20 bar with preference for ⁇ 30 bar, higher than Pc with illustrative upper limits being 100 bar, 200 bar and 300 bar higher than Pc.
  • the temperature typically means temperatures within (1.0-4.0) ⁇ Tc or in the interval of ⁇ 5° C., suitably ⁇ 10° C. with preference for ⁇ 15° C. above Tc with illustrative upper limits being 10° C., 40° C. and 50° C. above Tc.
  • Variant (ii) means that at least one of temperature and pressure, with preference for only the temperature, is/are below the critical value.
  • Tc and Pc respectively.
  • the temperature may be in the interval of (0.1-1) ⁇ Tc, such as (0.5-1) ⁇ Tc, or lower. Further, the temperature may be low, such as ⁇ 10° C. or ⁇ 30° C. These temperatures may be combined with pressures as defined in the preceding paragraph or with pressures lower than the Pc of the used antisolvent. For carbon dioxide this means that the temperarture in the particle formation function is ⁇ +31° C., such as about +25° C. or lower combined with a pressure above or below 74 bar.
  • the antisolvents of group (b) above are typically used in the subcritical state, i.e. as a subcritical fluid.
  • a method of producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, comprising
  • said polymeric stabilizing and matrix-forming component is present in said solvent.
  • said polymeric stabilizing and matrix-forming component is present in said antisolvent.
  • At least one of said fluid streams is a supercritical fluid stream, preferably a super- or subcritical CO 2 fluid stream.
  • said stream of antisolvent is a super- or subcritical CO 2 fluid stream.
  • said stream of solvent is a super- or subcritical CO 2 fluid stream.
  • said at least one polymeric stabilizing and matrix-forming component is present in said super- or subcritical CO 2 fluid stream.
  • said stream of solvent is a subcritical CO 2 fluid stream.
  • Said super- or subcritical CO 2 fluid stream is preferably provided at about 25° C. or lower, at a pressure of from about 100 to about 150 bar.
  • Said stream of solvent may, however, comprise e.g. nitrogen, methane, ethane, propane, ethylene, methanol, ethanol, acetone, water or a mixture of these compounds such as a mixture of CO 2 and nitrogen.
  • a further solvent such as an organic solvent (e.g. methanol, acetone) or aqueous solution (e.g. water) may be added as modifier into a super-/sub-critical solvent.
  • said stream of antisolvent is a super- or subcritical CO 2 fluid stream.
  • Said super- or subcritical CO 2 fluid stream is preferably provided at about 25° C. or lower, at a pressure of from about 100 to about 150 bar.
  • Said stream of antisolvent may, however, comprise e.g. nitrogen, methane, ethane, propane, ethylene, methanol, ethanol, acetone, water or a mixture of these compounds such as a mixture of CO 2 and nitrogen.
  • a solvent such as an organic solvent (e.g. methanol, acetone) or aqueous solution (e.g. water) may be added as modifier into a super- or subcritical antisolvent.
  • the polymeric stabilizing and matrix-forming component of the present in the methods of the invention includes, but not limited to, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. HPC ef, HPC If and HPC jf), hydroxypropyl methylcellulose (e.g. Methocel E3 and E15 and Pharmacoat), hydroxypropyl methylcellulose acetate succinate (HPMC AS), hydroxypropyl methylcellulose phthalate (e.g. HPMCP HP55), polyvinylpyrrolidone (e.g. PVP 30K and PVP 90K), polyvinyl acetate phthalate (PVAP), copolyvidone (e.g.
  • Kollidon VA 64 crospovidon (e.g. Kollidon CL), methacrylic acid and ethylacrylate copolymer (e.g. Kollicoat ME), methacrylate acid and methyl methacrylate copolymer (e.g. Eudragit L100), polyethylene glycol (PEG), DL lactide/glycolide copolymer, poly DL-lactide, cellulose acetate phthalate (CAP), carbomer homopolymer Type A (Carbopol 971P), carbomer homopolymer Type B (Carbopol 974P), aminoalkyl methacrylate copolymers (e.g. Eudragit RL100, RL PO or RS PO) and Poloxamers (e.g. Pluronics, Kolliphor).
  • PEG polyethylene glycol
  • CAP cellulose acetate phthalate
  • Carbopol 971P carbomer homopolymer Type A
  • Carbopol 974P Carbopol
  • said polymeric stabilizing and matrix-forming component is selected from methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinylpyrrolidone, polyvinyl acetate phthalate, copolyvidone, crospovidon, methacrylic acid and ethylacrylate copolymer, methacrylate acid and methyl methacrylate copolymer, polyethylene glycol, DL lactide/glycolide copolymer, poly DL-lactide, cellulose acetate phthalate, carbomer homopolymer Type A, carbomer homopolymer Type B, aminoalkyl methacrylate copolymers, and Poloxamers.
  • said polymeric stabilizing and matrix-forming component is selected from hydroxypropyl methylcellulose phthalate, hydroxypropyl cellulose, copolyvidon, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate phthalate and polyvinylpyrrolidone.
  • a solubilizer is added to the hybrid nanoparticles obtained in step c.
  • the solubilizer will be present separately from the particles.
  • Said solubilizer may be selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer, d- ⁇ -tocopherol acid polyethylene glycol 1000 succinate and a hydrogenated castor oil, such as PEG-40 hydrogenated castor oil or PEG-35 hydrogenated castor oil.
  • said solubilizer may be a poloxamer.
  • the methods of the invention provide stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, which display increased dissolution rate.
  • hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, wherein said hybrid nanoparticles display an increased dissolution rate of said protein kinase inhibitor, compared to the dissolution rate of said protein kinase inhibitor in raw, crystalline form.
  • said dissolution rate is measured by a flow through cell system in sink conditions, e.g., according to the US Pharmacopea (USP4).
  • Dissolution measurement in sink conditions of hybrid nanoparticles may be measured in a method consisting of adding the wished amount of powder into a flow through cell system (SOTAX, Allschwill, Switzerland), mounting the cell onto its apparatus and then pumping the appropriate medium (typically FaSSIF, FeSSIF, SGF) through the powder.
  • the temperature of the apparatus is typically set to 37° C.
  • the amount of powder added into the cell depends on drug load of the powder: The exact amount of powder can be calculated from results obtained from drug load analysis of the powders.
  • the PKI may be added into the flow through cell and a flow rate between 5 and 25 ml medium/min is pumped through the powder.
  • One ml samples of the medium passing through the cell is collected at predetermined times and subsequently analyzed by HPLC (e.g. C18 column Eclipse, 4.6 mm ⁇ 15 cm, 1 ml/min, detection 254 to 400 nm). Samples are typically taken after 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35 and 40 min from the moment the medium comes out from the flow through cell.
  • the accumulated % solubilized of the amount of active substance added into the flow through cell can be calculated and plotted against time (min).
  • the initial slope (“initial dissolution rate”, representing 0-10 minutes) of the graph may be estimated and taken as the dissolution rate of the material in sink condition at 37° C. in the given dissolution medium.
  • the dissolution rate is measured within the initial 0 to 10 minutes of dissolution.
  • the increased dissolution rate is preferably measured in a solution as a dissolution rate ratio of said hybrid nanoparticles and said protein kinase inhibitor in raw, crystalline form.
  • Preferably said ratio is from about 1.5:1 to about 500:1, such as from about 10:1 to about 30:1.
  • the dissolution rate is measured in a solution with intestinal pH, such as FaSSIF or FeSSIF or in a solution with gastric pH, such as SGF.
  • a solution with intestinal pH such as FaSSIF or FeSSIF
  • a solution with gastric pH such as SGF
  • said dissolution rate is measured by a flow through cell system, for instance in sink conditions.
  • Dissolution measurement in sink conditions of hybrid nanoparticles may be measured in a method consisting of adding the wished amount of powder into a flow through cell system (SOTAX, Allschwill, Switzerland), mounting the cell onto its apparatus and then pumping the appropriate medium (typically FaSSIF, FeSSIF, SGF) through the powder.
  • the temperature of the apparatus is typically set to 37° C.
  • the amount of powder added into the cell depends on drug load of the powder: The exact amount of powder can be calculated from results obtained from drug load analysis of the powders.
  • the PKI may be added into the flow through cell and a flow rate between 5 and 25 ml medium/min is pumped through the powder.
  • a method of producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, which produces particles that provides a solubility increase of inhibitor in a solution, said increase measured as the area under the curve (AUC) during about from 40 minutes to about 90 minutes, in said solution as compared with the AUC of inhibitor in raw, crystalline form.
  • said increase is from about 2:1 to about 10000:1, wherein 1 represents AUC of inhibitor in raw, crystalline form.
  • said increase is measured in a solution with gastric pH, such as SGF, or measured in a solution with intestinal pH, such as FaSSIF or FeSSIF.
  • the methods may produce particles that provide a solubility increase of inhibitor in a solution up to supersaturation, said increase measured as the area under the curve (AUC) during about from 40 minutes to about 90 minutes, in said solution as compared with the AUC of inhibitor in raw, crystalline form.
  • AUC area under the curve
  • a method of producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, characterized by providing an amorphous powder X-ray diffraction pattern.
  • a method of producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, wherein the dissolution rate of said stable, amorphous hybrid nanoparticles remain stable to at least about 90%, after 6 months of storage or more, at room temperature.
  • said protein kinase inhibitor is a tyrosine kinase inhibitor selected from the group consisting of lapatinib, pazopanib, nilotinib, erlotinib, dasatinib, gefitinib, sorafenib, crizotinib, vemurafenib and axitinib; or salts or hydrates or solvates thereof, or combinations thereof. In some embodiments it may be advantageous to use other PKIs.
  • PKI examples include, but are not limited to afatinib, bosutinib, cediranib, fostamatinib, imatinib, lenvatinib, lestaurtinib, motesanib, mubritinib, pegaptanib, ruxolitinib, semaxanib, sunitinib, tandunitib, tipifamib and vandetanib; or salts or hydrates or solvates thereof, or combinations thereof.
  • said hybrid nanoparticles has an average particle diameter size of less than about 1000 nm, such as less than about 500 nm, preferably less than 250 nm.
  • said solvent is an organic solvent selected from DMSO and trifluoroethanol, or a mixture of these solvents, or mixture of these solvents with other organic solvent such as DMSO/acetone, DMSO/tetrahydrofurane or trifluoroethanol/ethyl acetate.
  • said particles further comprise a solubilizer within the particles.
  • Said solubilizer may be polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer, d-a-tocopherol acid polyethylene glycol 1000 succinate, or a hydrogenated castor oil, such as PEG-40 hydrogenated castor oil or PEG-35 hydrogenated castor oil.
  • the method further comprises formulating the particles retained in step (c) as a pharmaceutical composition containing the particles and optionally further pharmaceutically acceptable excipents.
  • stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, obtainable by the methods described above.
  • the hybrid nanoparticles produced by the methods of the present invention may also dissolve and the protein kinase inhibitor may be systemically absorbed independently of the pH in the surrounding environment, and typically approximately in equal amounts, especially at both a gastric pH, such as from about pH 1.2 to about pH 2.1, preferably about 1.7 and at a intestinal pH such as from about pH 4.5 to about pH 8, preferably at a pH of about 6.
  • a gastric pH such as from about pH 1.2 to about pH 2.1, preferably about 1.7 and at a intestinal pH such as from about pH 4.5 to about pH 8, preferably at a pH of about 6.
  • systemically absorbed is meant that the protein kinase inhibitor is released from the hybrid nanoparticles and taken up by the systemic blood stream. Therefore, in another embodiment of this aspect, there is provided a method, wherein said protein kinase inhibitor is systemically absorbed independently of the pH.
  • said protein kinase inhibitor is systemically absorbed with approximately equal amounts at both a gastric pH and at an intestinal
  • the concentration of protein kinase inhibitor in the blood stream, after exposure is approximately similar. This may be illustrated by a ratio, wherein the concentration of protein kinase inhibitor in the blood stream is measured after administration in gastric pH conditions (A) and compared with the concentration of protein kinase inhibitor in the blood stream is measured after administration in intestinal pH conditions (N). Typically, the ratio A:N is from about 0.75:1 to about 1.5:1 and preferably from about 1:1 to about 1.25:1.
  • the concentration measurement of protein kinase inhibitor in the blood stream may be carried out as an area under the curve (AUC) during 0-24 hours, the maximum concentration (Cmax) or as bioavailability.
  • a method of producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, wherein the concentration of systemically absorbed protein kinase inhibitor in gastric pH conditions compared with the concentration of systemically absorbed protein kinase inhibitor in intestinal pH conditions is in a ratio of from about 0.75:1 to about 1.5:1, preferably of from about 1:1 to about 1.25:1.
  • said gastric pH condition represents a pH of about 1.4
  • said intestinal pH condition represents a pH of about 6.
  • the concentration is measured as area under the curve (AUC) during 0-24 hours of exposure of the composition or as the maximum concentration (Cmax).
  • the amounts of systemically absorbed protein kinase inhibitor may be measured in various ways. There is provided, in Example 14 in the present disclosure, a method for measurement of systemically absorbed protein kinase inhibitors at various pHs, i.e. under both acid and neutral conditions.
  • a method of producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, which produces a solubility increase of inhibitor in a solution up to supersaturation, said increase measured as the area under the curve (AUC) during about 90 minutes, in said solution and compared with the AUC of inhibitor in crystalline form.
  • AUC area under the curve
  • Said increase may be from to about 2:1 to about 1000:1, wherein 1 represents AUC of inhibitor in crystalline form.
  • the hybrid nanoparticles produced by the methods of the invention will dissolve in vivo in the different environments of the stomach, small intestine, large intestine and colon, it is important to choose an appropriate solution for in vitro dissolution testing. It is critical that the in vitro test conditions mimic the in vivo environment as closely as possible, for example pH and osmolarity. Typically, for intestinal uptake, the pH is between 6 and 7. Therefore, the solution may hold a pH from about pH 6 to about pH 7, such as about pH 6.5.
  • the solution for testing has a pH from about pH 4.5 to about pH 8, such as about pH 6.5 or such as about pH 5.
  • the solutions may represent Fasted Simulated State Intestinal Fluid (FaSSIF) or Fed Simulated State Intestinal Fluid (FeSSIF).
  • the pH is between 1 and 2. Therefore, the solution may hold a pH from about pH 1 to about pH 2, such as about pH 1.4. Therefore, in embodiments of the invention, the solution for testing may represent Simulated Gastric Fluid (SGF).
  • SGF Simulated Gastric Fluid
  • a method of producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component and further a solubilizer selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer, d- ⁇ -tocopherol acid polyethylene glycol 1000 succinate, Poloxamers (e.g. Pluronics, Kolliphor) and a hydrogenated castor oil, such as PEG-40 hydrogenated castor oil or PEG-35 hydrogenated castor oil.
  • a solubilizer selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer, d- ⁇ -tocopherol acid polyethylene glycol 1000 succinate, Poloxamers (e.g. Pluronics, Kolliphor) and a hydrogenated castor oil, such as PEG-40 hydrogenated castor oil or PEG-35 hydrogenated castor oil.
  • said solubilizer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolyme or a hydrogenated castor oil, such as PEG-40 hydrogenated castor oil or PEG-35 hydrogenated castor oil.
  • Nilotinib HCl powder with HPC EF HPMC (e.g. Methocel) and poloxamer (e.g. Lutrol® F127) result in hybrid nanoparticles with different dissolution profiles.
  • HPMC e.g. Methocel
  • poloxamer e.g. Lutrol® F127
  • the amount of PKI in the hybrid nanoparticles produced by the methods of the present invention may be less or more, such as wherein the amount of PKI in the hybrid nanoparticles is from about 0.01% by weight to about 99.9% by weight.
  • hybrid nanoparticles produced by the methods of the present invention, wherein the amount of PKI in the hybrid nanoparticles is from about 10% by weight to about 70% by weight.
  • hybrid nanoparticles produced by the methods of the present invention, wherein the amount of PKI in the hybrid nanoparticles is from about 10% by weight to about 50% by weight.
  • the amount of PKI in the hybrid nanoparticles is from 5% by weight to about 50% by weight, from 10% by weight to about 40% by weight, from about 10% by weight to about 30% by weight, or from about 10% by weight to about 20% by weight.
  • Control of the characteristics of the particles may be convenient for specific applications.
  • Particle size, particle agglomeration, particles porosity and the choice and ratio of the polymeric stabilizing and matrix-forming agent could be modified in order to increase or decrease the surface area to volume ratio of the particle or behaviour of the particles in a gastroinstestinal fluids, leading to an increase or decrease of the dissolution rate.
  • Dependent on the desired dissolution characteristics such particles characteristics may be adapted.
  • particles with differents characteristics may be present in the same pharmaceutical composition to provide an initial dose and a prolonged or delayed dose of active ingredient. Additionally, it may be advantageous to provide different PKIs and/or other active ingredient(s) in different primary particles with different characteristics adapted to provide desired dissolution rates for each active ingredient(s).
  • compositions comprising the hybrid nanoparticles obtainable by the methods of the invention.
  • Such compositions may further comprise at least one pharmaceutically acceptable solubilizer.
  • Said solubilizer may be present separated from the hybrid nanoparticles in the composition or be randomly intermixed with the hybrid nanoparticles in the pharmaceutical composition.
  • the pharmaceutical composition may also be in a dosage form consisting of several layers, for example laminated or multilayered tablets, such that the hybrid nanoparticles are separated from the solubilizer.
  • the solubilizer may be selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer, d- ⁇ -tocopherol acid polyethylene glycol 1000 succinate and a hydrogenated castor oil, such as PEG-40 hydrogenated castor oil or PEG-35 hydrogenated castor oil. Said solubilizer may also be a poloxamer.
  • stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, obtainable by methods of the present invention.
  • step (c) there is provided a method of the present invention, further comprising formulating the particles retained in step (c) as a pharmaceutical composition containing the particles and optionally further pharmaceutically acceptable excipents.
  • a protein kinase inhibitor in the hybrid nanoparticles produced by the methods of the present invention required for use in treatment will vary not only with the particular inhibitor selected but also with the route of administration, the nature of the condition for which treatment is required and the age, weight and condition of the patient and will be ultimately at the discretion of the attendant physician.
  • a suitable dose may be in the range of from about 0.005 to about 30 mg/kg of body weight per day, preferably in the range of 0.05 to 10 mg/kg/day.
  • the desired dose is conveniently presented in a single dose or as a divided dose administered at appropriate intervals, for example as two, three, four or more doses per day.
  • the desired dose may also be, for example, once every two days, once every three days, or even once a week.
  • compositions of the invention are conveniently administered in unit dosage form; for example containing 0.5 to 1500 mg, conveniently 1 to 1000 mg, most conveniently 5 to 700 mg of active ingredient per unit dosage form.
  • the compositions of the invention will normally be administrated via the oral, parenteral, intravenous, intramuscular, subcutaneous or other injectable ways, buccal, rectal, vaginal, transdermal and/or nasal route and/or via inhalation, in a pharmaceutically acceptable dosage form.
  • the compositions may be administered at varying doses.
  • compositions include but are not limited to those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • the compositions may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy.
  • Pharmaceutical compositions suitable for oral administration are conveniently presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active substance.
  • Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
  • the tablets may be coated according to methods well known in the art.
  • compositions may be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • parenteral administration e.g. by injection, for example bolus injection or continuous infusion
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilizing and/or dispersing agents.
  • compositions may be adapted to give sustained release of the active inhibitor.
  • compositions produced by the methods of the present invention.
  • I represents the protein kinase inhibitor (PKI);
  • P represents the polymeric stabilizing and matrix-forming component
  • I+P represents a physical mix of the inhibitor with the polymeric stabilizing and matrix-forming component, i.e. without further processing;
  • I+S represents a physical mix of the inhibitor with the solubilizer
  • I+P+S represents a physical mix of the inhibitor, the polymeric stabilizing and matrix-forming component and the solubilizer
  • I/P represents hybrid nanoparticles with the inhibitor and the polymeric stabilizing and matrix-forming component
  • I/P+S represents hybrid nanoparticles with the inhibitor and the polymeric stabilizing and matrix-forming component and a separate solubilizer added;
  • I/P/S represents hybrid nanoparticles with the inhibitor, the polymeric stabilizing and matrix-forming component and the solubilizer.
  • the hybrid nanoparticles were produced with exemplary PKIs, polymeric stabilizing and matrix-forming components (“Polymers”), solubilizers, solution concentrations, ratios, solvents, antisolvents, temperatures and pressures as set out below and in Table A.
  • Polymers polymeric stabilizing and matrix-forming components
  • solubilizers solubilizers
  • solution concentrations concentrations, ratios, solvents, antisolvents, temperatures and pressures as set out below and in Table A.
  • the pressure in the precipitation chamber was set to about 100-175 bar and the temperature was set to about 10 to 50° C. Both streams contact within the nozzle and the hybrid nanoparticles were formed and subsequently collected in the particle in the collecting chamber.
  • solubilizer For I/P/S type particles, a defined amount of solubilizer is added and dissolved into the PKI/polymer solution before pumping the solution through the nozzle for precipitation according to the methods described above.
  • solubilizer For I/P+S type particles, a defined amount of solubilizer is added to the hybrid nanoparticles in a glass vial. The glass vial is slowly rotated for mixing of the solubilizer with the hybrid nanoparticles.
  • HPC If (1:2) & CO2 & 150 Bars Nilotinib base/ 501 5% 40% TFE 15° C.
  • HPMCP HP55 & CO 2 & 125 Bars Pazopanib HCl/ 521 3.6% 35% TFE 25° C.
  • PVP 90K & CO 2 & 150 Bars Sorafenib 561 4% 35% DMSO/Acetone 40° C. tosylate/ (1:2) & CO2 & 150 Bars HPMCP HP55 Vemurafenib/ 168, 170 & 5% 25% DMSO 25° C.
  • the method consists of adding the wished amount of powder of hybrid nanoparticles into a glass vial and then pouring in it the appropriate medium (typically FaSSIF, FeSSIF or SGF).
  • the medium was prepared in accordance with the manufacturer's instructions.
  • the amount of powder added depends on the wished “total PKI concentration”. For some experiments where powders with high drug loads were tested and compared, the real amount of PKI in the hybrid nanoparticles was not taken in account. For other experiments, the drug load was first estimated by HPLC and the amount of powder to obtain the drug concentration was calculated.
  • the powder was added in a 8 mL glass bottle and 7 mL of solution was added (typically FaSSIF, FeSSIF or SGF).
  • the glass bottle was put on a shaker (approximately 1 rotation per minute) for dissolution.
  • Samples of 500 ⁇ l where taken after different times, and subsequently centrifuged at approximately 15000 g for 3 minutes.
  • the resulting supernatant was then analyzed by HPLC (C 18 column Eclipse, 4.6 mm ⁇ 15 cm, 1 mL/min, detection at 254-400 nM. Generally samples were taken after 5, 30 and 90 min and eventually 150 min.
  • nilotinib base or nilotinib HCl represented the protein kinase inhibitor.
  • the experiments were carried out by measuring concentration of solubilized PKI (mg/L) after 5, 30 and 90 minutes dissolution in a solution at about pH 6.5, namely FaSSIF (Fasted State Simulated Intestinal Fluid). Further, experiments were caried out in an alternative solution at about pH 5, namely FeSSIF (Fed State Simulated Intestinal Fluid). Samples of the solution were taken at various time intervals and the amount of protein kinase inhibitor was measured by the dissolution measurement assay described above.
  • FaSSIF solution Representative results in FaSSIF solution are provided below in Table 1 and 2, where Table 1 provides data of concentration of nilotinib HCl (mg/L) after 5, 30 and 90 minutes dissolution, whereas Table 2 provides data of % solubilized nilotinib HCl after 30 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 90 minutes dissolution and the AUC increase of hybrid nanoparticles, compared to nilotinib HCl in raw, crystalline form added to the solution (experiments 1-40).
  • Tables 3 and 4 there is provided dissolution data in FeSSIF solution, presented similarly as Table 1 and 2 (experiments 41-55).
  • Table 5 provides data from a comparative experiment with similar hybrid nanoparticles, carried out in FaSSIF and FeSSIF, respectively (experiments 56-57).
  • Table 6 presents further comparative data for experiments carried out in FaSSIF and FeSSIF, respectively, with hybrid nanoparticles produced by the methods of the invention.
  • Nilotinib concentration of nilotinib HCl (mg/L) after 5, 30 and 90 minutes dissolution in FaSSIF solution (pH 6.5).
  • Drug Polymeric load stab. matrix.
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min 1 I Nilotinib HCl 100 — — 0.1 0.2 0.1 (raw) 100 mg 2 I Nilotinib HCl 100 — — 0.2 0.2 0.2 (raw) 500 mg 3 I Nilotinib HCl 100 — — 0.2 0.3 0.2 (raw) 1000 mg 4 I Nilotinib Base 100 — — 0.6 0.5 0.2 (raw) 500 mg 5 I + P Nilotinib HCl 100 HPMCP HP55 — 0.2 0.5 0.5 (raw) 2000 mg 1000 mg 6 I + P Nilotinib HCl 100 PVAP — 1.3 0.2 0.4 (raw) 2000 mg 1000 mg 7 I + P Nilotinib HCl 100 Eudragit L100 — 0.2 0.4 0.2 (raw) 2000 mg 1000 mg 8 I + P Nilotinib HCl 100 Methocel E15 — 0.1 0.1 0.1 (raw) 2000 mg 1000 mg 9
  • Nilotinib concentration of nilotinib HCl (mg/L) after 5, 30 and 90 minutes dissolution in FeSSIF solution (pH 5).
  • Drug Polymeric load stab. matrix.
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min 41 I Nilotinib HCl 100 — — 0.6 0.9 0.9 (raw) 500 mg 42 I + P + S Nilotinib HCl 100 HPMCP HP55 Soluplus 0.4 0.6 1.0 (raw) 750 mg 715 mg 500 mg 43 I + P + S Nilotinib HCl 100 HPMCP HP55 Soluplus 0.2 0.2 0.3 (raw) 750 mg 1000 mg 500 mg 44 I + P + S Nilotinib HCl 100 PVAP Soluplus 0.5 0.9 1.1 (raw) 750 mg 715 mg 500 mg 45 I + P + S Nilotinib HCl 100 PVAP TPGS 0.2 0.4 0.5 (raw) 750 mg 1000 mg 500 mg 46 I/P Nilotinib HCl 40 HPMCP HP55 — 16.2 45.6 63.3 500 mg 750 mg 47 I/P Nilotinib HCl 40 PVAP — 3 7.7 11.2 500 mg
  • Nilotinib concentration of nilotinib HCl (mg/L) after 5, 30, 90 and 150 minutes dissolution in FaSSIF and FeSSIF solution, respectively.
  • Drug Polymeric Conc load stab. matrix.
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min min 56 I/P + S Nilotinib HCl 40 HPMCP HP55 Soluplus 51.2 66 62.3 53.2 FaSSIFF 75 mg 112.5 mg 715 mg 57 I/P + S Nilotinib HCl 40 HPMCP HP55 Soluplus 24.8 43.1 50.7 53 FeSSIFF 75 mg 112.5 mg 715 mg
  • Nilotinib concentration of nilotinib HCl (mg/L) after 5, 30, 90 and 150 minutes dissolution in FaSSIF and FeSSIF solution, respectively presented as comparative data.
  • Drug Polymeric Compare load stab. matrix. Compare Compare Compare (%) ratio Component Solubilizer (%) (%) (%) 150 Exp Comp.
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min min 2 & 41 I Nilotinib HCl 100 — 300 450 225 — (raw) 1000 mg 12 & 42 I + P + S Nilotinib HCl 100 HPMCP HP55 Soluplus 100 200 250 — (raw) 750 mg 715 mg 500 mg 18 & 46 I/P Nilotinib HCl 40 HPMCP HP55 — 156 912 1711 — 100/500 mg 150/750 mg 30 & 48 I/P + S Nilotinib HCl 40 HPMCP HP55 Soluplus 33 64 301 — 500 mg 750 mg 715 mg 56 & 57 I/P + S Nilotinib HCl 40 HPMCP HP55 Soluplus 48 65 81 100 (raw) 112.5 mg 715 mg 75 mg 37 & 52 I/P/S Nilotinib HCl 40 HPMCP HP55 Soluplus 163 516 663 — 500 mg 750 mg 7
  • FaSSIF and FeSSIF The results carried out in FaSSIF and FeSSIF, respectively, indicate that the stable, amorphous hybrid nanoparticles produced by the methods of the invention provide a similar increase in solubility.
  • One issue with PKI formulation is the food effect.
  • Several of the PKIs are labeled for administration in fasted state despite the fact that food in most cases increases their bioavailability. Low bioavailability might partly explain the digestive problems that are associated with the PKIs.
  • the similar dissolution rate in FaSSIF and FeSSIF indicates that the hybrid nanoparticles produced by the methods of the invention (e.g. experiments 56/57) may reduce food effect and patient digestive problems by its solubility improvement that allows reducing dosage.
  • hybrid nanoparticles produced by the methods of the invention may be given in conjunction with food intake.
  • erlotinib HCl represented the PKI.
  • the experiments were carried out by measuring concentration of PKI (mg/L) after 5, 30 and 90 minutes dissolution in a solution at about pH 6.5, namely FaSSIF (Fasted State Simulated Intestinal Fluid). Further, experiments were carried out in an alternative solution at about pH 5, namely FeSSIF (Fed State Simulated Intestinal Fluid). Samples of the solution were taken at various time intervals and the amount of PKI was measured by the dissolution measurement assay described above.
  • FaSSIF solution Representative results in FaSSIF solution are provided below in Table 7 and 8, where Table 7 provides data of concentration of erlotinib HCl (mg/L) after 5, 30 and 90 minutes dissolution, whereas Table 8 provides data of % solubilized erlotinib HCl after 30 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 90 minutes dissolution and the AUC increase of hybrid nanoparticles produced by the methods of the invention, compared to erlotinib HCl in raw, crystalline form added to the solution (experiments 58-68).
  • Tables 9 and 10 there is provided dissolution data in FeSSIF solution, presented similarly as Table 7 and 8 (experiments 69-73).
  • Table 11 data from a comparative experiment with similar hybrid nanoparticles produced by the methods of the invention, carried out in FaSSIF and FeSSIF, respectively (experiments 74-83).
  • Table 12 presents further comparative data for experiments carried out in FaSSIF and FeSSIF, respectively, with stable, amorphous hybrid nanoparticles produced by the methods of the invention.
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min 58 I Erlotinib HCl 100 — — 28.9 6.25 4.6 (raw) 1000 mg 59 I + P Erlotinib HCl 100 HPMC-AS — 23 53.2 84 (raw) 1000 mg 2000 mg 60 I + S Erlotinib HCl 100 — Soluplus 92.8 156.6 176 (raw) 1000 mg 715 mg 61 I + S Erlotinib HCl 100 — TPGS 51.4 14.7 11.6 (raw) 1000 mg 1000 mg 62 I + P + S Erlotinib HCl 100 HPMC-AS Soluplus 96.7 256.6 361.8 (raw) 1000 mg 1850 mg 715 mg 63 I + P + S Erlotinib HCl 100 HPMC-AS TPGS 81.3 188.1 256.6 (raw) 1000 mg 1850 mg 1000 mg 64 I/P Erlotinib HCl 35 HPMC-AS — 83.4 79.6 44.8 1000 mg 18
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min 69 I Erlotinib HCl 100 — — 156.8 189.9 196 (raw) 1000 mg 70 I + P + S Erlotinib HCl 100 HPMC-AS Soluplus 25.5 75.1 126.2 (raw) 1000 mg 1850 mg 715 mg 71 I/P Erlotinib HCl 35 HPMC-AS — 258.2 402.1 464.5 1000 mg 1850 mg 72 I/P + S Erlotinib HCl 35 HPMC-AS Soluplus 260.1 422.8 498.8 1000 mg 1850 mg 715 mg 73 I/P/S Erlotinib HCl 28 HPMC-AS Soluplus 293.6 395.2 434.9 1000 mg 1850 mg 715 mg
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min 74 I + P + S Erlotinib HCl 100 HPMC-AS Soluplus 134.1 369.8 533.4 FaSSIF (raw) 1850 mg 1430 mg 1000 mg 75 I + P + S Erlotinib HCl 100 HPMC-AS Soluplus 24.4 88.8 154.4 FeSSIF (raw) 1850 mg 1430 mg 1000 mg 76 I/P + S Erlotinib HCl 35 HPMC-AS Soluplus 275.4 441.4 508 FaSSIF 1000 mg 1850 mg 1430 mg 77 I/P + S Erlotinib HCl 35 HPMC-AS Soluplus 292.2 476.2 546.5 FeSSIF 1000 mg 1850 mg 1430 mg 78 I/P + S Erlotinib HCl 23 HPMC-AS Soluplus 90.4 108 114.8 FaSSIF 1000 mg 1850 mg 1430 mg 79 I/P + S Erlotinib HCl 23 HPMC-AS Soluplus 25
  • Inhibitor (I) (%) (P) izer (S) 5 min 30 min 90 min 58 & 69 I Erlotinib HCl 100 — — 543 3038 4261 (raw) 1000 mg 74 & 75 I + P + S Erlotinib HCl 100 HPMC-AS Soluplus 18 24 29 (raw) 1850 mg 1430 mg 1000 mg 80 & 81 I + P + S Erlotinib HCl 100 HPMC-AS Soluplus 21 26 34 (raw) 925 mg 715 mg 500 mg 64 & 71 I/P Erlotinib HCl 35 HPMC-AS — 310 505 1037 1000 mg 1850 mg 76 & 77 I/P + S Erlotinib HCl 35 HPMC-AS Soluplus 106 108 108 1000 mg 1850 mg 1430 mg 82 & 83 I/P + S Erlotinib HCl 35 HPMC-AS Soluplus 98 94 95 500 mg 925 mg 715 mg 78 &
  • solubilizer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer (Soluplus) and d- ⁇ -tocopherol acid polyethylene glycol 1000 succinate (TPGS). This improvement was not observed when the solubilizer was incorporated into the hybrid nanoparticles produced by the methods of the invention.
  • hybrid nanoparticles produced by the methods of the invention may reduce food effect and patient digestive problems by its equal solubility improvement in both FaSSIF and FeSSIF (experiment 76/77 and 82/83) that moreover potentially may allow reducing of dosage.
  • FaSSIF and FeSSIF experiment 76/77 and 82/83
  • stable, amorphous hybrid nanoparticles produced by the methods of the invention may be given in conjunction with food intake.
  • pazopanib represented the PKI.
  • the experiments were carried out by measuring concentration of PKI (mg/L) after 5, 30 and 90 minutes dissolution in a solution at about pH 6.5, namely FaSSIF (Fasted State Simulated Intestinal Fluid). Further, experiments were carried out in an alternative solution at about pH 5, namely FeSSIF (Fed State Simulated Intestinal Fluid). Samples of the solution were taken at various time intervals and the amount of PKI was measured by the dissolution measurement assay described above.
  • FaSSIF solution Representative results in FaSSIF solution are provided below in Table 13 and 14, where Table 13 provides data of concentration of pazopanib (mg/L) after 5, 30 and 90 minutes dissolution, whereas Table 14 provides data of % solubilized pazopanib after 30 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 90 minutes dissolution and the AUC increase with hybrid nanoparticles produced by the methods of the invention, compared to pazopanib in raw, crystalline form added to the solution (experiments 84-93).
  • Tables 15 and 16 there is provided dissolution data in FeSSIF solution, presented similarly as Table 13 and 14 (experiments 94-101).
  • Table 17 data from a comparative experiment with similar hybrid nanoparticles produced by the methods of the invention, carried out in FaSSIF and FeSSIF, respectively (experiments 102-109).
  • Table 18 presents further comparative data for experiments carried out in FaSSIF and FeSSIF, respectively, with hybrid nanoparticles produced by the methods of the invention.
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min 84 I Pazopanib (raw) 100 — — 46.2 24.4 15.0 1000 mg 85 I + P Pazopanib (raw) 100 PVP 90K — 82.7 83.8 67.7 1000 mg 2000 mg 86 I + S Pazopanib (raw) 100 — Soluplus 116.3 177.7 204.3 1000 mg 357 mg 87 I + S Pazopanib (raw) 100 — Soluplus 177.6 270.8 324.2 1000 mg 715 mg 88 I + P + S Pazopanib (raw) 100 PVP 90K Soluplus 198.8 312.2 394.1 1000 mg 1857 mg 715 mg 89 I + P + S Pazopanib (raw) 100 PVP 90K TPGS 182.6 196.7 49.2 1000 mg 1857 mg 1000 mg 90 I/P Pazopanib 35 PVP 90K — 89.4 103.4 92.8 1000 mg 1857 mg 91 I/P + S Pazo
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min 94 I Pazopanib (raw) 100 — — 231.3 321.4 239.3 1000 mg 95 I + P Pazopanib (raw) 100 PVP 90K — 234.8 309.7 269.7 1000 mg 2000 mg 96 I + S Pazopanib (raw) 100 — Soluplus 209.3 309.6 229.1 1000 mg 357 mg 97 I + P + S Pazopanib (raw) 100 PVP 90K Soluplus 307.5 475.3 578.0 1000 mg 1857 mg 715 mg 98 I + P + S Pazopanib (raw) 100 PVP 90K TPGS 320.9 395.1 325.6 1000 mg 1857 mg 1000 mg 99 I/P Pazopanib 35 PVP 90K — 348.4 362.1 335.8 1000 mg 1857 mg 100 I/P + S Pazopanib 35 PVP 90K Soluplus 450.0 684.4 777.6 1000 mg 1857 mg 715 mg 101 I/
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min 102 I + P + S Pazopanib (raw) 100 PVP 90K Soluplus 76.8 113.8 139.6 FaSSI 300 mg 557 mg 428 mg F 103 I + P + S Pazopanib (raw) 100 PVP 90K Soluplus 116.7 193.6 246.9 FeSSI 300 mg 557 mg 428 mg F 104 I/P + S Pazopanib 35 PVP 90K Soluplus 154.7 214.7 223 FaSSI 300 mg 557 mg 428 mg F 105 I/P + S Pazopanib 35 PVP 90K Soluplus 186 273.3 303.1 FeSSI 300 mg 557 mg 428 mg F 106 I + P + S Pazopanib (raw) 100 PVP 90K Soluplus 261.1 421.6 508.5 FaSSI 1000 mg 1857 mg 1428 mg F 107 I + P + S Pazopanib (raw) 100 PVP 90K Soluplus 275.8 49
  • Inhibitor (I) (%) (P) izer (S) 5 min 30 min 90 min 84 & 94 I Pazopanib 100 — — 501 1317 1595 (raw) 1000 mg 85 & 95 I + P Pazopanib 100 PVP 90K — 284 370 398 (raw) 1857 mg 1000 mg 87 & 96 I + S Pazopanib 100 — Soluplus 118 114 71 (raw) 715 mg 1000 mg 88 & 97 I + P + S Pazopanib 100 PVP 90K Soluplus 155 152 147 (raw) 1857 mg 715 mg 1000 mg 102 & I + P + S Pazopanib 100 PVP 90K Soluplus 152 170 177 103 (raw) 557 mg 428 mg 300 mg 90 & 99 I/P Pazopanib 35 PVP 90K — 390 350 362 1000 mg 1857 mg 89 & I/P + S Pazopanib 35 PVP 90K Soluplus 188
  • solubilizer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer (Soluplus) and d- ⁇ -tocopherol acid polyethylene glycol 1000 succinate (TPGS). This improvement was not observed when the solubilizer was incorporated into the hybrid nanoparticles produced by the methods of the invention.
  • FaSSIF and FeSSIF The results carried out in FaSSIF and FeSSIF, respectively, indicates that the hybrid nanoparticles produced by the methods of the invention provide a similar increase in solubility.
  • One issue with PKI formulation is the food effect.
  • Several of the PKIs are labeled for administration in fasted state despite the fact that food in most cases increases their bioavailability. Low bioavailability might partly explain the digestive problems that are associated with the PKIs.
  • the similar dissolution rate in FaSSIF and FeSSIF indicates that the hybrid nanoparticles produced by the methods of the invention may reduce food effect and patient digestive problems by its equal solubility improvement in both FaSSIF and FeSSIF (experiments 89/100 and 104/105) that moreover allows reducing dosage.
  • amorphous hybrid nanoparticles produced by the methods of the invention may be given in conjunction with food intake.
  • lapatinib base or lapatinib ditosylate salt represented the PKI.
  • the experiments were carried out by measuring concentration of PKI (mg/L) after 5, 30 and 90 minutes dissolution in a solution at about pH 6.5, namely FaSSIF (Fasted State Simulated Intestinal Fluid). Samples of the solution were taken at various time intervals and the amount of PKI was measured by the dissolution measurement assay described above.
  • FaSSIF solution Representative results in FaSSIF solution are provided below in Table 19 and 20, where Table 19 provides data of concentration of lapatinib (mg/L) after 5, 30 and 90 minutes dissolution, whereas Table 20 provides data of % solubilized lapatinib after 30 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 90 minutes dissolution and the AUC increase with hybrid nanoparticles produced by the methods of the invention, compared to non-formulated lapatinib ditosylate salt added to the solution (experiments 110-126).
  • Table 19 provides data of concentration of lapatinib (mg/L) after 5, 30 and 90 minutes dissolution
  • Table 20 provides data of % solubilized lapatinib after 30 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 90 minutes dissolution and the AUC increase with hybrid nanoparticles produced by the methods of the invention, compared to non-formulated lapatinib ditosylate salt added to
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min 110 I Lapatinib (base) 100 — — 2.9 6.0 6.5 2000 mg 111 I Lapatinib (salt) 100 — — 57.7 132.2 124.2 2000 mg 112 I + S Lapatinib (salt) 100 — Soluplus 67.6 142.9 140.0 2000 mg 285 mg 113 I + S Lapatinib (salt) 100 — Soluplus 144.7 283.6 204.0 2000 mg 645 mg 114 I + P Lapatinib (base) 100 HPC LF — 1.9 4.9 6.1 2000 mg 4000 mg 115 I + P Lapatinib (salt) 100 HPC LF — 56.7 93.8 81.8 2000 mg 4000 mg 116 I + P + S Lapatinib (base) 100 HPC LF Soluplus 5.5 22.5 52.0 660 mg 340 mg 715 mg 117 I + P + S Lapatinib (salt) 100 HP
  • the experiments 122-125 clearly shows that a solubility increase is obtained with stable, amorphous hybrid nanoparticles produced by the methods of the invention, with lapatinib, in particular lapatinib base and a polymeric stabilizing and matrix-forming component, wherein a separate solubilizer is added to the composition.
  • Particular improvements are achieved with the polymeric stabilizing and matrix-forming component hydroxypropyl cellulose EF and hydroxypropyl cellulose LF.
  • solubilizer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer (Soluplus) and d- ⁇ -tocopherol acid polyethylene glycol 1000 succinate (TPGS).
  • nilotinib HCl represented the PKI.
  • the experiments were carried out by measuring concentration of PKI (mg/L) after 5, 30 and 90 minutes dissolution in a solution at about pH 1.4, namely SGF (Simulated Gastric Fluid). Samples of the solution were taken at various time intervals and the amount of PKI was measured by the dissolution measurement assay described above. Representative results in SGF solution are provided below in Table 21, which provides percentage of solubilized nilotinib HCl from both a physical mix with nilotinib HCl in raw, crystalline form and hybrid nanoparticles produced by the methods of the invention after 5, 30 and 90 minutes dissolution.
  • Nilotinib present in the physical mix of nilotinib HCl raw with the polymeric stabilizing and matrix-forming component PVAP and the solubilizer Soluplus (Exp. 129) is dissolved completely within 5 minutes in SGF while nilotinib is only partially dissolved after 90 min in SGF with hybrid nanoparticles produced by the methods of the invention, wherein the components are comprised as hybrid nanoparticles, with the addition of a solubilizer (Exp. 128) or without the addition of a solubilizer (Exp. 127).
  • Nilotinib HCl-concentration of nilotinib HCl (mg/L) after 5, 30 and 90 minutes dissolution in SGF solution (pH 1.4).
  • Drug Polymeric load stab. matrix. % % % ratio Component Solubilizer solubilized solubilized solubilized Exp Comp.
  • Inhibitor (I) (%) (P) (S) 5 min 30 min 90 min 127 I/P Nilotinib HCl 100 PVAP — 32 40 42 500 mg 750 mg 128 I/P + S Nilotinib HCl 100 PVAP Soluplus 38 48 50 500 mg 750 mg 715 mg 129 I + P + S Nilotinib HCl 100 PVAP Soluplus 100 100 100 (raw) 750 mg 715 mg 1000 mg
  • the experiments 127-129 shows that a nilotinib HCl, in stable, amorphous hybrid nanoparticles produced by the methods of the invention (exp 127 and 128) are partially solubilized at pH 1.4.
  • the stable, amorphous hybrid nanoparticles produced by the methods with a enteric coating polymer such as PVAP is partially protected from the acidic environment.
  • gefitinib represented the PKI.
  • the experiments were carried out by measuring concentration of PKI (mg/L) after 3, 40 and 80 minutes dissolution in a solution at about pH 6.5, namely FaSSIF (Fasted State Simulated Intestinal Fluid). Samples of the solution were taken at various time intervals and the amount of PKI was measured by the dissolution measurement assay described above.
  • FaSSIF solution Representative results in FaSSIF solution are provided below in Table 22 and 23, where Table 22 provides data of concentration of gefitinib (mg/L) after 3, 40 and 80 minutes dissolution, whereas Table 23 provides data of % solubilized gefitinib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase with hybrid nanoparticles produced by the methods of the invention, compared to non-formulated gefitinib added to the solution (experiments 131-137).
  • Table 22 provides data of concentration of gefitinib (mg/L) after 3, 40 and 80 minutes dissolution
  • Table 23 provides data of % solubilized gefitinib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase with hybrid nanoparticles produced by the methods of the invention, compared to non-formulated gefitinib added to the solution (experiments 131-137).
  • the experiments 131-137 show that a solubility increase is obtained with stable, amorphous hybrid nanoparticles produced by the methods of the invention, with gefitinib, in particular gefitinib and a polymeric stabilizing and matrix-forming component, wherein a separate solubilizer is added to the composition.
  • a separate solubilizer is added to the composition.
  • the polymeric stabilizing and matrix-forming component polyvinylpyrrolidone K-30 (PVP 30K) and hydroxy propyl methyl cellulose phthalate (HPMCP HP55).
  • improvements are achieved by the addition of a separate solubilizer added, wherein said solubilizer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer (Soluplus).
  • FaSSIF solution Representative results in FaSSIF solution are provided below in Table 24 and 25, where Table 24 provides data of concentration of dasatinib (mg/L) after 3, 40 and 80 minutes dissolution, whereas Table 25 provides data of % solubilized dasatinib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase with hybrid nanoparticles produced by the methods of the invention, compared to non-formulated dasatinib added to the solution (experiments 138-141).
  • Table 24 provides data of concentration of dasatinib (mg/L) after 3, 40 and 80 minutes dissolution
  • Table 25 provides data of % solubilized dasatinib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase with hybrid nanoparticles produced by the methods of the invention, compared to non-formulated dasatinib added to the solution (experiments 138-141).
  • Experiments 138-141 show that a solubility increase is obtained with stable, amorphous hybrid nanoparticles produced by the methods of the invention, with dasatinib, in particular dasatinib and a polymeric stabilizing and matrix-forming component, wherein a separate solubilizer is added to the composition.
  • a separate solubilizer is added to the composition.
  • said solubilizer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer (Soluplus).
  • sorafenib tosylate represented the PKI.
  • the experiments were carried out by measuring concentration of PKI (mg/L) after 3, 40 and 80 minutes dissolution in a solution at about pH 6.5, namely FaSSIF (Fasted State Simulated Intestinal Fluid). Samples of the solution were taken at various time intervals and the amount of PKI was measured by the dissolution measurement assay described above.
  • FaSSIF Fested State Simulated Intestinal Fluid
  • FaSSIF solution Representative results in FaSSIF solution are provided below in Table 26 and 27, where Table 26 provides data of concentration of sorafenib (mg/L) after 3, 40 and 80 minutes dissolution, whereas Table 27 provides data of % solubilized sorafenib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase of compositions, compared to non-formulated sorafenib tosylate added to the solution (experiments 142-145).
  • Table 26 provides data of concentration of sorafenib (mg/L) after 3, 40 and 80 minutes dissolution
  • Table 27 provides data of % solubilized sorafenib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase of compositions, compared to non-formulated sorafenib tosylate added to the solution (experiments 142-145).
  • Sorafenib tosylate concentration of sorafenib (mg/L) after 3, 40 and 80 minutes dissolution in FaSSIF solution (pH 6.5).
  • Drug Polymeric load stab. matrix.
  • Inhibitor (I) (%) (P) (S) 3 min 40 min 80 min 142 I Sorafenib 100 — — 59.1 343.5 311.5 tosylate (raw) 1000 mg 143 I + P + S Sorafenib 35 HPMCP HP55 Soluplus 33.9 297.1 352.2 tosylate (raw) 1850 mg 715 mg 1000 mg 144 I/P Sorafenib 35 HPMCP HP55 — 245.3 520.3 613.8 tosylate 1850 mg 1000 mg 145 I/P + S Sorafenib 35 HPMCP HP55 Soluplus 335.1 1202.6 1738.1 tosylate 1850 mg 715 mg 2000 mg
  • nilotinib base represented the PKI.
  • the experiments were carried out by measuring concentration of PKI (mg/L) after 3, 40 and 80 minutes dissolution in a solution at about pH 6.5, namely FaSSIF (Fasted State Simulated Intestinal Fluid). Samples of the solution were taken at various time intervals and the amount of PKI was measured by the dissolution measurement assay described above.
  • Nilotinib base concentration of nilotinib base (mg/L) after 3, 40 and 80 minutes dissolution in FaSSIF solution (pH 6.5).
  • Drug Polymeric load stab. matrix.
  • Inhibitor (I) (%) (P) (S) 3 min 40 min 80 min 146 I/P Nilotinib base 40 HPMCP HP55 — 12.7 5.3 3.7 500 mg 750 mg 147 I/P Nilotinib base 40 PVAP — 12.3 8.6 7.0 500 mg 750 mg 148 I/P + S Nilotinib base 40 HPMCP HP55 Soluplus 136.8 88.8 41.2 500 mg 750 mg 715 mg 149 I/P + S Nilotinib base 40 PVAP Soluplus 20.7 115.9 60.4 500 mg 750 mg 715 mg
  • crizotinib represented the PKI.
  • the experiments were carried out by measuring concentration of PKI (mg/L) after 3, 40 and 80 minutes dissolution in a solution at about pH 6.5, namely FaSSIF (Fasted State Simulated Intestinal Fluid). Samples of the solution were taken at various time intervals and the amount of PKI was measured by the dissolution measurement assay described above.
  • FaSSIF solution Representative results in FaSSIF solution are provided below in Table 30 and 31, where Table 30 provides data of concentration of crizotinib (mg/L) after 3, 40 and 80 minutes dissolution, whereas Table 31 provides data of % solubilized crizotinib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase with stable, amorphous hybrid nanoparticles produced by the methods of the invention, compared to non-formulated crizotinib added to the solution (experiments 150-156).
  • Table 30 provides data of concentration of crizotinib (mg/L) after 3, 40 and 80 minutes dissolution
  • Table 31 provides data of % solubilized crizotinib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase with stable, amorphous hybrid nanoparticles produced by the methods of the invention, compared to non-formulated crizot
  • Inhibitor (I) (%) (P) (S) 3 min 40 min 80 min 150 I Crizotinib (raw) 100 — — 89.3 226.5 295.6 1000 mg 151 I + P + S Crizotinib (raw) 25 PVP30K Soluplus 176.2 368.5 414.6 1000 mg 3000 mg 715 mg 152 I + P + S Crizotinib (raw) 25 PVP30K Cremophor 161.2 428.4 497.7 1000 mg 3000 mg RH40 715 mg 153 I/P Crizotinib 25 PVP30K — 325.9 390.4 398.8 1000 mg 3000 mg 154 I/P Crizotinib 25 Kollidon VA64 — 297.5 447.6 449.9 1000 mg 3000 mg 155 I/P + S Crizotinib 25 PVP30K Soluplus 457.6 581.4 578.9 1000 mg 3000 mg 715 mg 156 I/P + S Crizotinib 25 PVP
  • Experiments 150-156 show that a solubility increase is obtained with stable, amorphous hybrid nanoparticles produced by the methods of the invention, with crizotinib, in particular crizotinib and a polymeric stabilizing and matrix-forming component, wherein a separate solubilizer is added to the composition.
  • Particular improvements are achieved with the polymeric stabilizing and matrix-forming component polyvinylpyrrolidone K-30 (PVP 30K) and copolyvidone (Kollidon VA64).
  • solubilizer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer (Soluplus) and PEG-40 hydrogenated castor oil (Cremophor RH40).
  • axitinib represented the PKI.
  • the experiments were carried out by measuring concentration of PKI (mg/L) after 3, 40 and 80 minutes dissolution in a solution at about pH 6.5, namely FaSSIF (Fasted State Simulated Intestinal Fluid). Samples of the solution were taken at various time intervals and the amount of PKI was measured by the dissolution measurement assay described above.
  • FaSSIF solution Representative results in FaSSIF solution are provided below in Table 32 and 33, where Table 32 provides data of concentration of axitinib (mg/L) after 3, 40 and 80 minutes dissolution, whereas Table 33 provides data of % solubilized axitinib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase with stable, amorphous hybrid nanoparticles produced by the methods of the invention, compared to non-formulated axitinib added to the solution (experiments 157-163).
  • Table 32 provides data of concentration of axitinib (mg/L) after 3, 40 and 80 minutes dissolution
  • Table 33 provides data of % solubilized axitinib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase with stable, amorphous hybrid nanoparticles produced by the methods of the invention, compared to non-formulated
  • Inhibitor (I) (%) (P) (S) 3 min 40 min 80 min 157 I Axitinib (raw) 100 — — 0.6 0.6 0.6 500 mg 158 I + P + S Axitinib (raw) 25 Kollidon VA64 Soluplus 0.2 0.8 4.3 500 mg 1500 mg 715 mg 159 I + P + S Axitinib (raw) 25 HPMC AS Soluplus 0.2 3.0 3.1 500 mg 1500 mg 715 mg 160 I/P Axitinib 25 Kollidon VA64 — 71.1 25.9 9.1 500 mg 1500 mg 161 I/P Axitinib 25 HPMC AS — 17.6 21.0 16.4 500 mg 1500 mg 162 I/P + S Axitinib 25 Kollidon VA64 Soluplus 77.6 223.6 266.1 500 mg 1500 mg 715 mg 163 I/P + S Axitinib 25 HPMC AS Soluplus 40.3 110.3 129.9 500 mg 1500 mg 715 mg
  • Experiments 157-163 show that a solubility increase is obtained with stable, amorphous hybrid nanoparticles produced by the methods of the invention, with axitinib, in particular axitinib and a polymeric stabilizing and matrix-forming component, wherein a separate solubilizer is added to the composition.
  • axitinib in particular axitinib and a polymeric stabilizing and matrix-forming component
  • a separate solubilizer is added to the composition.
  • Particular improvements are achieved with the polymeric stabilizing and matrix-forming component copolyvidone (Kollidon VA64) and hydroxypropyl methylcellulose acetate succinate (HPMC AS).
  • improvements are achieved by the addition of a separate solubilizer added, wherein said solubilizer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer (Soluplus).
  • vemurafenib represented the PKI.
  • the experiments were carried out by measuring concentration of PKI (mg/L) after 3, 40 and 80 minutes dissolution in a solution at about pH 6.5, namely FaSSIF (Fasted State Simulated Intestinal Fluid). Samples of the solution were taken at various time intervals and the amount of PKI was measured by the dissolution measurement assay described above.
  • FaSSIF Fested State Simulated Intestinal Fluid
  • FaSSIF solution Representative results in FaSSIF solution are provided below in Table 34 and 35, where Table 34 provides data of concentration of vemurafenib (mg/L) after 3, 40 and 80 minutes dissolution, whereas Table 35 provides data of % solubilized vemurafenib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase with stable, amorphous hybrid nanoparticles produced by the methods of the invention, compared to non-formulated vemurafenib added to the solution (experiments 164-170).
  • Table 34 provides data of concentration of vemurafenib (mg/L) after 3, 40 and 80 minutes dissolution
  • Table 35 provides data of % solubilized vemurafenib after 40 minutes dissolution, the Area Under the Curve (AUC—mg/min/L) during 80 minutes dissolution and the AUC increase with stable, amorphous hybrid nanoparticles produced by the methods of
  • Vemurafenib Concentration of vemurafenib (mg/L) after 3, 40 and 80 minutes dissolution in FaSSIF solution (pH 6.5).
  • Drug Polymeric load stab. matrix.
  • Inhibitor (I) (%) (P) (S) 3 min 40 min 80 min 164 I Vemurafenib (raw) 100 — — 0.3 0.3 0.4 500 mg 165 I + P + S Vemurafenib (raw) 25 Kollidon VA64 Soluplus 0.2 0.2 0.4 500 mg 1500 mg 715 mg 166 I + P + S Vemurafenib (raw) 25 CAP Soluplus 0.1 0.2 0.4 500 mg 1500 mg 715 mg 167 I/P Vemurafenib 25 Kollidon VA64 — 35.5 107.6 122.9 500 mg 1500 mg 168 I/P Vemurafenib 25 CAP — 75.1 47.5 11.8 500 mg 1500 mg 169 I/P + S Vemurafenib 25 Kollidon VA64 Soluplus 27.4 111.3 172.3 500 mg 1500 mg 715 mg 170 I/P + S Vemurafenib 25 CAP Soluplus 55.4 105.7 118.9 500 mg 1500 mg 715 mg
  • Experiments 164-170 show that a solubility increase is obtained with stable, amorphous hybrid nanoparticles produced by the methods of the invention, with vemurafenib, in particular vemurafenib and a polymeric stabilizing and matrix-forming component, wherein a separate solubilizer is added to the composition.
  • a separate solubilizer is added to the composition.
  • Particular improvements are achieved with the polymeric stabilizing and matrix-forming component copolyvidone (Kollidon VA64) and cellulose acetate phthalate (CAP).
  • improvements are achieved by the addition of a separate solubilizer added, wherein said solubilizer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer (Soluplus).
  • Dissolution measurement in sink conditions of stable, amorphous hybrid nanoparticles produced by the methods of the invention were measured in a method consisting of adding the wished amount of powder into a flow through cell system (SOTAX, Allschwill, Switzerland), mounting the cell onto its apparatus and then pumping the appropriate medium (typically FaSSIF, FeSSIF, SGF) through the powder.
  • the temperature of the apparatus was set to 37° C.
  • the amount of powder added into the cell depends on drug load of the powder: The exact amount of powder was calculated from results obtained from drug load analysis of the powders.
  • Each experiment comprises a comparison between the PKI in raw form with stable, amorphous hybrid nanoparticles produced by the methods of the invention with the inhibitor and a representative polymeric stabilizing and matrix-forming component.
  • Experiments 500-501 show that the initial dissolution rate of the stable, amorphous hybrid nanoparticles produced by the methods of the invention, with nilotinib base, is superior to the initial dissolution rate of nilotinib HCl in raw, crystalline form.
  • Experiments 510-511 show that the initial dissolution rate of the stable, amorphous hybrid nanoparticles produced by the methods of the invention, with erlotinib HCl, is superior to the initial dissolution rate of erlotinib HCl in raw, crystalline form.
  • Experiments 520-521 show that the initial dissolution rate of the stable, amorphous hybrid nanoparticles produced by the methods of the invention, with pazopanib HCl, is superior to the initial dissolution rate of pazopanib HCl in raw, crystalline form.
  • Experiments 530-531 show that the initial dissolution rate of the stable, amorphous hybrid nanoparticles produced by the methods of the invention, with lapatinib base, is superior to the initial dissolution rate of lapatinib ditosylate in raw, crystalline form.
  • Experiments 540-541 show that the initial dissolution rate of the stable, amorphous hybrid nanoparticles produced by the methods of the invention, with gefitinib, is superior to the initial dissolution rate of the gefinib in raw, crystalline form.
  • Experiments 550-551 show that the initial dissolution rate of the stable, amorphous hybrid nanoparticles produced by the methods of the invention, with dasatinib, is superior to the initial dissolution rate of the dasatinib raw, crystalline form.
  • Experiments 560-561 show that the initial dissolution rate of the stable, amorphous hybrid nanoparticles produced by the methods of the invention, with sorafenib tosylate, is superior to the initial dissolution rate of sorafenib tosylate in raw, crystalline form.
  • Experiments 570-571 show that the initial dissolution rate of the stable, amorphous hybrid nanoparticles produced by the methods of the invention, with crizotinib, is superior to the initial dissolution rate of crizotinib in raw, crystalline form.
  • Experiments 580-582 show that the initial dissolution rate of the stable, amorphous hybrid nanoparticles produced by the methods of the invention, with axitinib, is superior to the initial dissolution rate of axitinib in raw, crystalline form.
  • the stable, amorphous hybrid nanoparticles tested are as set out in experiments 146-149, in Example 9.
  • stomach contents of the dogs were either neutralized with a sodium bicarbonate solution 5 min prior to capsule dosing or acidified with an HCl—KCl buffer 10 min prior to dose.
  • One group of dogs also received a single iv dose (1 mg/kg) of nilotinib.
  • Plasma levels of nilotinib were determined with a selective LC-MS/MS method. There were no side-effects observed in any animal studied.
  • IV data were obtained by constant rate IV infusion of 1 mg/kg, of a solution of Nilotinib at 0.2 mg/mL, in a 10% HP ⁇ CD, pH adjustment to pH 3.3 to 3.5.
  • IV data were obtained by constant rate IV infusion of 1 mg/kg, of a solution of Nilotinib at 0.2 mg/mL, in a 10% HP ⁇ CD, pH adjustment to pH 3.3 to 3.5.
  • nilotinib formulation administrated to an acidified stomach showed plasma levels about 2 times higher than those after the same formulation administered to a neutralized stomach.
  • Both formulations comprising stable, amorphous hybrid nanoparticles produced by the methods of the invention with nilotinib base with PVAP and HPMCP HP55 as polymeric stabilizing and matrix-forming components showed significant improvements in plasma exposure, with plasma levels about 2-fold higher than those of the marketed formulation given to an acidified stomach.
  • combining hybrid nanoparticles produced by the methods of the invention could give a plasma exposure that is be more or less independent of stomach pH.
  • hybrid nanoparticles produced by the methods of the invention with nilotinib base with PVAP and HPMCP HP55 as polymeric stabilizing and matrix-forming components, where the solubilizer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer was added and administered to an acidified stomach resulted in plasma levels 2.3- to 3.1-fold higher than those of the marketed formulation.
  • amorphous hybrid nanoparticles produced by the methods of the invention it was shown that particles were stable over at least 11 months at room temperature (18-25° C.), as measured by X-Ray powder diffraction and dissolution rate by measurement of AUC.
  • the resulting particles provided stable, amorphous hybrid nanoparticles at 40% drug load (I/P nilotinib base/HPMCP HP55: exp 146), as measured by XRPD as well as dissolution rate by measurement of AUC.
  • the material showed one glass transition temperature at ca 127° C., which indicate a single amorphous phase with inherent stability. Partially crystalline batches also processed similar inherent stability. 6 months storage at room temperature (18-25° C.) of partly crystalline hybrid nanoparticles at 40% drug load, I/P nilotinib base/HPMCP HP55, did not show any signs of physical instability.
  • mDSC Modulated Differential Scanning calorimetry
  • mDSC Modulated Differential Scanning calorimetry
  • Samples were weighed to 7 ⁇ 2 mg in Tzero Low—mass aluminum pans and sealed with Tzero lids. They were then heated at a heating rate of 3° C./min from 0 to 170° C. with conventional modulation temperature amplitude of 1° C. and a modulation period of 40 seconds. Ultra-high purity nitrogen was used as purge gas at a flow rate of 50 mL/min. All data analyses were performed using TA Universal Analysis software, version 4.7A. Cell constant and temperature calibrations were conducted with the use of an indium standard prior to instrument operation. DSC results were evaluated in terms of both forward and reverse components of heat flow.
  • Thermogravimetry was performed on a Seiko TG/DTA 6200 and open 90 ⁇ l Pt-pans with ca 10 to 20 mg of sample and a nitrogen flow of 200 m L/min.
  • the temperature program was ambient (20° C.) to 400° C. with a heating rate of 10° C./min.
  • a blank was subtracted and the TG data was normalized with respect to sample size and analyzed using the Muse Standard Analysis software, version 6.1 U.
  • the hygroscopicity of the samples was studied by Dynamic Vapor Sorption Gravimetry (DVS), using a DVS-1 (Surface Measurement Ltd., UK). Approximately 10 mg of the substance was weighed into a glass cup. The relative weight was recorded at 20 second interval when the target relative humidity (RH) over the sample was increased stepwise from 0% to 90%, and then similarly decreased back to 0% RH, with 10% RH per step. Each sample was run in three consecutive full cycles. The condition to proceed to the next level of RH was a weight change below or equal to 0.002% within 15 minutes, with a maximum total time per step of 24 hours. Due to slow equilibration in experiments of this type, the numbers obtained should be regarded as lower estimates of water uptake. The temperature was kept at 25° C.
  • XRD experiments were run on an X'Pert Pro diffractometer (PANanalytical, Almelo, Netherlands) set in Bragg-Brentano geometry.
  • the diffractometer was equipped with 20 ⁇ m nickel filter and an X'Celerator RTMS detector with an active length of 2.122° 2 ⁇ .
  • a representative sample was placed on a zero background quarts single crystal specimen support (Siltronix, Archamps, France).
  • Experiments were run using Cu K ⁇ radiation (45 kV and 40 mA) at ambient temperature and humidity.
  • Scans were run in continuous mode in the range 4.5-40° 2 ⁇ using automatic divergence and anti-scatter slits with observed length of 10 mm, a common counting time of 299.72 seconds, and step size of 0.0167° 2 ⁇ .
  • Data collection was done using the application software X'Pert Data Collector V.2.2j and instrument control software V.2.1E, while pattern analysis was done using X'Pert Data Viewer V.1.2c (all software being from PANanalytical, Almelo, Netherlands).
  • Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer was added to enhance solubility.
  • a comparison of the AUC over 80 minutes show clearly that the dissolution rate profile of the particles is practically unchanged after 11 months storage, e.g. the ratio between the AUC of particles produced and tested, compared to particles produced, tested and stored for 11 months is over 97%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Window Of Vehicle (AREA)
US14/371,843 2012-01-13 2013-01-11 Novel methods Abandoned US20140378454A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/371,843 US20140378454A1 (en) 2012-01-13 2013-01-11 Novel methods

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261586187P 2012-01-13 2012-01-13
SE1250015-3 2012-01-13
SE1250015 2012-01-13
US201261713120P 2012-10-12 2012-10-12
SE1251160-6 2012-10-12
SE1251160 2012-10-12
PCT/SE2013/050015 WO2013105894A1 (en) 2012-01-13 2013-01-11 A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
US14/371,843 US20140378454A1 (en) 2012-01-13 2013-01-11 Novel methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2013/050015 A-371-Of-International WO2013105894A1 (en) 2012-01-13 2013-01-11 A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/153,807 Division US20160250153A1 (en) 2012-01-13 2016-05-13 Novel methods

Publications (1)

Publication Number Publication Date
US20140378454A1 true US20140378454A1 (en) 2014-12-25

Family

ID=48781736

Family Applications (19)

Application Number Title Priority Date Filing Date
US14/371,875 Active 2033-05-31 US9456992B2 (en) 2012-01-13 2013-01-11 Pharmaceutical composition comprising stable, amorphous, hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix forming component
US14/371,843 Abandoned US20140378454A1 (en) 2012-01-13 2013-01-11 Novel methods
US15/153,807 Abandoned US20160250153A1 (en) 2012-01-13 2016-05-13 Novel methods
US15/248,107 Active US9827230B2 (en) 2012-01-13 2016-08-26 Pharmaceutical compositions
US15/423,136 Active US9833442B2 (en) 2012-01-13 2017-02-02 Pharmaceutical compositions
US15/423,183 Active US9833443B2 (en) 2012-01-13 2017-02-02 Pharmaceutical compositions
US15/791,093 Active US10143683B2 (en) 2012-01-13 2017-10-23 Pharmaceutical compositions
US16/173,466 Active US10314829B2 (en) 2012-01-13 2018-10-29 Pharmaceutical compositions
US16/176,101 Active US10314830B2 (en) 2012-01-13 2018-10-31 Pharmaceutical compositions
US16/404,027 Active US10555937B2 (en) 2012-01-13 2019-05-06 Pharmaceutical compositions
US16/404,059 Active US10561645B2 (en) 2012-01-13 2019-05-06 Pharmaceutical compositions
US16/403,969 Active US10561643B2 (en) 2012-01-13 2019-05-06 Pharmaceutical compositions
US16/404,004 Active US10561644B2 (en) 2012-01-13 2019-05-06 Pharmaceutical compositions
US16/784,498 Active US10772877B2 (en) 2012-01-13 2020-02-07 Pharmaceutical compositions
US16/995,880 Active US11241419B2 (en) 2012-01-13 2020-08-18 Pharmaceutical compositions
US17/552,768 Active 2033-03-27 US11963951B2 (en) 2012-01-13 2021-12-16 Pharmaceutical compositions
US17/671,157 Active US11426391B2 (en) 2012-01-13 2022-02-14 Pharmaceutical compositions
US17/671,207 Active US11376243B2 (en) 2012-01-13 2022-02-14 Pharmaceutical compositions
US17/829,736 Active US11517562B2 (en) 2012-01-13 2022-06-01 Pharmaceutical compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/371,875 Active 2033-05-31 US9456992B2 (en) 2012-01-13 2013-01-11 Pharmaceutical composition comprising stable, amorphous, hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix forming component

Family Applications After (17)

Application Number Title Priority Date Filing Date
US15/153,807 Abandoned US20160250153A1 (en) 2012-01-13 2016-05-13 Novel methods
US15/248,107 Active US9827230B2 (en) 2012-01-13 2016-08-26 Pharmaceutical compositions
US15/423,136 Active US9833442B2 (en) 2012-01-13 2017-02-02 Pharmaceutical compositions
US15/423,183 Active US9833443B2 (en) 2012-01-13 2017-02-02 Pharmaceutical compositions
US15/791,093 Active US10143683B2 (en) 2012-01-13 2017-10-23 Pharmaceutical compositions
US16/173,466 Active US10314829B2 (en) 2012-01-13 2018-10-29 Pharmaceutical compositions
US16/176,101 Active US10314830B2 (en) 2012-01-13 2018-10-31 Pharmaceutical compositions
US16/404,027 Active US10555937B2 (en) 2012-01-13 2019-05-06 Pharmaceutical compositions
US16/404,059 Active US10561645B2 (en) 2012-01-13 2019-05-06 Pharmaceutical compositions
US16/403,969 Active US10561643B2 (en) 2012-01-13 2019-05-06 Pharmaceutical compositions
US16/404,004 Active US10561644B2 (en) 2012-01-13 2019-05-06 Pharmaceutical compositions
US16/784,498 Active US10772877B2 (en) 2012-01-13 2020-02-07 Pharmaceutical compositions
US16/995,880 Active US11241419B2 (en) 2012-01-13 2020-08-18 Pharmaceutical compositions
US17/552,768 Active 2033-03-27 US11963951B2 (en) 2012-01-13 2021-12-16 Pharmaceutical compositions
US17/671,157 Active US11426391B2 (en) 2012-01-13 2022-02-14 Pharmaceutical compositions
US17/671,207 Active US11376243B2 (en) 2012-01-13 2022-02-14 Pharmaceutical compositions
US17/829,736 Active US11517562B2 (en) 2012-01-13 2022-06-01 Pharmaceutical compositions

Country Status (15)

Country Link
US (19) US9456992B2 (pl)
EP (7) EP2802314B1 (pl)
JP (13) JP6238311B2 (pl)
CN (4) CN107115318A (pl)
AU (8) AU2013208323B2 (pl)
CA (2) CA2860932C (pl)
DK (2) DK3181122T3 (pl)
ES (2) ES2946549T3 (pl)
FI (2) FI3181122T3 (pl)
HR (2) HRP20230529T1 (pl)
IL (4) IL293775B2 (pl)
IN (1) IN2014DN06529A (pl)
MX (4) MX347456B (pl)
PL (3) PL2802314T3 (pl)
WO (2) WO2013105894A1 (pl)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019088662A1 (ko) * 2017-10-31 2019-05-09 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2802314T3 (da) * 2012-01-13 2021-01-25 Xspray Microparticles Ab Fremgangsmåde til fremstilling af stabile, amorfe hybride nanopartikler, der omfatter mindst én proteinkinaseinhibitor og mindst én polymer stabiliserende og matrixdannende bestanddel
WO2013105894A1 (en) 2012-01-13 2013-07-18 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
BR112014030424A8 (pt) 2012-06-04 2017-07-11 Pharmacyclics Inc Formas cristalinas de um inibidor de quinase de tirosina de bruton
JP6356678B2 (ja) 2012-09-17 2018-07-11 ファイザー・インク 治療用ナノ粒子を製造する方法
CN104367557A (zh) * 2013-08-12 2015-02-25 浙江九洲药业股份有限公司 无定型药物活性成分与pvp组合物的制备方法
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
AP2016009494A0 (en) 2014-03-14 2016-10-31 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
WO2015145145A1 (en) * 2014-03-24 2015-10-01 Cipla Limited Pharmaceutical composition comprising lapatinib
WO2015145157A1 (en) * 2014-03-28 2015-10-01 Cipla Limited Pharmaceutical composition comprising pazopanib
WO2015200054A2 (en) 2014-06-24 2015-12-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
BR112017002231A2 (pt) * 2014-08-07 2018-07-17 Pharmacyclics Llc novas formulações de um inibidor de tirosina cinase de bruton
WO2016090240A1 (en) * 2014-12-04 2016-06-09 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
WO2016097011A1 (en) * 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising amorphous nilotinib
SI3265084T1 (sl) 2015-03-03 2024-04-30 Pharmacyclics Llc Farmacevtske formulacije inhibitorja Burtonove tirozin kinaze
KR20180088274A (ko) * 2015-03-24 2018-08-03 다우 글로벌 테크놀로지스 엘엘씨 폴리머의 수용액
CZ2015250A3 (cs) * 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
EP3393647A4 (en) 2015-12-22 2019-08-21 The Trustees of Princeton University PROCESS FOR CAPACITING SOLUBLE BIOLOGICS, THERAPEUTICS AND CONTRASTANTS
CN114209702A (zh) * 2016-03-17 2022-03-22 太阳制药工业公司 尼洛替尼的药物组合物
JP6739275B2 (ja) * 2016-08-02 2020-08-12 日本化薬株式会社 ゲフィチニブを有効成分とする医薬組成物
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
AU2018235447B2 (en) * 2017-03-15 2021-12-09 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[N'-(2chloro-6-methylbenzoyl)hydrazinocarbonyl]-2-methyl-phenylethynyl}-pyridin-2-yl)amide
EP3596050A4 (en) 2017-03-15 2021-01-13 Sun Pharma Advanced Research Company Limited NOVEL AMORPICAL DISPERSION OF 4-METHYL-3-QUINOLINE-3-YLETHINYL-BENZOIC ACID-N '- (2-CHLORO-6-METHYL-BENZOYL) HYDRACIDE
EP3606916A1 (en) 2017-04-06 2020-02-12 Johnson Matthey Public Limited Company Novel forms of afatinib dimaleate
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
WO2018203636A1 (ko) * 2017-05-02 2018-11-08 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
CN107157941B (zh) * 2017-05-16 2020-12-25 北京化工大学 一种达沙替尼纳米制剂及其制备方法
CN107011262B (zh) * 2017-06-01 2019-10-29 中国药科大学 一种基于超临界抗溶剂技术制备甲苯磺酸索拉非尼多晶型k微粒的方法
WO2019055539A1 (en) * 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
KR101922369B1 (ko) * 2018-01-12 2018-11-26 한국지질자원연구원 경구 생체이용률 개선을 위한 약물-층상형 실리케이트 복합체, 이를 포함하는 경구용 약학 조성물 및 상기 복합체의 제조 방법
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
WO2019246479A1 (en) 2018-06-22 2019-12-26 Johnson Matthey Public Limited Company Form of ponatinib
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
CN109833483B (zh) * 2018-09-17 2020-10-23 山东大学 基于小分子伴侣的索拉非尼纳米药物的制备
WO2020072870A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Co-crystal forms of baricitinib
CN109044977A (zh) * 2018-10-26 2018-12-21 武汉工程大学 一种乐伐替尼固体分散体及其制备方法和制剂
KR20210090201A (ko) * 2018-11-06 2021-07-19 베이징 이노케어 파마 테크 씨오., 엘티디. 6-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)니코틴아미드를 포함하는 무정형 고체 분산액
WO2020172120A1 (en) * 2019-02-18 2020-08-27 Slayback Pharma Llc Pharmaceutical compositions of nilotinib
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
CN110801434A (zh) * 2019-10-31 2020-02-18 金华职业技术学院 一种冻干法制备甲苯磺酸拉帕替尼固体分散体的方法
IL294928A (en) 2020-01-24 2022-09-01 Nanocopoeia Llc Amorphous solid dispersions of dasatinib and uses thereof
WO2021155254A1 (en) * 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
CN112294971B (zh) * 2020-02-20 2022-02-01 深圳市泰力生物医药有限公司 具有改进的溶解性的尼洛替尼组合物
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
IL297776A (en) 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
CN111467501B (zh) * 2020-05-22 2021-06-15 深圳市泰力生物医药有限公司 具有改良溶出性质的组合物
CN111973596B (zh) * 2020-06-15 2022-02-15 深圳市泰力生物医药有限公司 具有改良溶出性质的抗肺纤维化组合物
BR112023000501A2 (pt) * 2020-07-23 2023-01-31 Crititech Inc Partículas de lapatinibe e usos das mesmas
WO2022034914A1 (ja) * 2020-08-13 2022-02-17 カルナバイオサイエンス株式会社 易溶性固形製剤およびその製法
WO2022069661A1 (en) 2020-10-02 2022-04-07 Bend Research, Inc. Acetic acid as processing aid in spray drying for basic drugs
WO2022120512A1 (zh) * 2020-12-07 2022-06-16 天津睿创康泰生物技术有限公司 一种高生物利用度的索拉非尼药物组合物及应用
EP4281047A1 (en) 2021-01-21 2023-11-29 XSpray Pharma AB (publ) Fast dissolving pharmaceutical compositions of dasatinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
CN115671110B (zh) * 2021-07-30 2024-05-10 上海云晟研新生物科技有限公司 帕唑帕尼口服药物组合物、其制备方法及应用
KR20230114478A (ko) * 2022-01-25 2023-08-01 (주)피알지에스앤텍 프로게리닌을 포함하는 과립제 및 이를 이용한 샤셋제
WO2023155182A1 (zh) * 2022-02-21 2023-08-24 北京睿创康泰医药研究院有限公司 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物
CN116688139B (zh) * 2023-06-25 2024-03-29 深圳市新阳唯康科技有限公司 一种克唑替尼药物组合物及其制备方法和应用
CN117100715A (zh) * 2023-09-05 2023-11-24 深圳市泰力生物医药有限公司 一种含无定型尼洛替尼的胶囊及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US6406781B1 (en) * 1998-06-23 2002-06-18 3M Innovative Properties Company Stretch release adhesive article with stabilizer
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
SE0303476D0 (sv) 2003-12-22 2003-12-22 Censdelivery Ab Device, method and use for the formation of small particles
US7625911B2 (en) 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
WO2006123223A1 (en) 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
WO2007133750A2 (en) * 2006-05-12 2007-11-22 The Board Of Trustees Of The Leland Stanford Junior University Encapsulated nanoparticles for drug delivery
EP2043606A2 (en) * 2006-06-13 2009-04-08 Elan Pharma International Limited Nanoparticulate kinase inhibitor formulations
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2008122858A2 (en) 2007-04-05 2008-10-16 Pfizer Products Inc. Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
US7823700B2 (en) * 2007-07-20 2010-11-02 International Business Machines Corporation User identification enabled elevator control method and system
PL2229233T3 (pl) 2007-12-07 2020-03-31 Xspray Pharma Ab (Publ) Sposób wytwarzania cząstek
JP2009155282A (ja) * 2007-12-27 2009-07-16 Kowa Co 固体分散体含有医薬組成物
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2105130A1 (de) 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
GB0909154D0 (en) * 2008-09-25 2009-07-08 Nanomaterials Tech Pte Ltd A process for making particles for delivery of drug nanoparticles
US9050317B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
KR100924236B1 (ko) * 2009-06-23 2009-10-29 충남대학교산학협력단 균일한 입도분포를 가지는 초미세입자의 신규한 제조방법 및 장치
EP2579973A4 (en) 2010-06-14 2017-01-18 Xspray Microparticles Ab Apparatus and method for the production of particles
WO2013105894A1 (en) * 2012-01-13 2013-07-18 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
JP2017141910A (ja) * 2016-02-10 2017-08-17 武蔵精密工業株式会社 伝動装置
JP6688624B2 (ja) * 2016-02-11 2020-04-28 学校法人 名城大学 ガスタンク及びこのガスタンクを複数備えたガスの貯蔵供給設備
JP6767610B2 (ja) * 2016-02-12 2020-10-14 パナソニックＩｐマネジメント株式会社 断熱体とその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019088662A1 (ko) * 2017-10-31 2019-05-09 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US11007195B2 (en) 2018-06-15 2021-05-18 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US11052088B2 (en) 2018-06-15 2021-07-06 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US11160805B2 (en) 2018-06-15 2021-11-02 Handa Onocology, Llc Kinase inhibitor salts and compositions thereof

Also Published As

Publication number Publication date
EP2802316A1 (en) 2014-11-19
JP2017222693A (ja) 2017-12-21
CA2860932A1 (en) 2013-07-18
CA2860973A1 (en) 2013-07-18
IL233582A0 (en) 2014-08-31
US11963951B2 (en) 2024-04-23
JP2018172393A (ja) 2018-11-08
AU2019275513B2 (en) 2022-03-10
CA2860973C (en) 2021-10-26
US20170143683A1 (en) 2017-05-25
EP2802314A1 (en) 2014-11-19
EP4218740A1 (en) 2023-08-02
US20190060294A1 (en) 2019-02-28
JP6351810B2 (ja) 2018-07-04
WO2013105894A1 (en) 2013-07-18
AU2018200933B2 (en) 2020-01-02
IN2014DN06529A (pl) 2015-06-12
MX2020000984A (es) 2020-07-13
IL233583A0 (en) 2014-08-31
CN104159577B (zh) 2017-03-15
HRP20230529T1 (hr) 2023-09-15
JP6463416B2 (ja) 2019-02-06
CN104159577A (zh) 2014-11-19
EP2802314A4 (en) 2015-08-12
AU2021269328A1 (en) 2021-12-09
PL3181128T3 (pl) 2023-07-31
JP7006995B2 (ja) 2022-01-24
JP2018035147A (ja) 2018-03-08
JP2018008973A (ja) 2018-01-18
DK3181122T3 (da) 2023-06-06
US20190275018A1 (en) 2019-09-12
JP6238311B2 (ja) 2017-11-29
JP6628834B2 (ja) 2020-01-15
US11517562B2 (en) 2022-12-06
AU2013208324B2 (en) 2017-11-23
EP3181128B1 (en) 2023-03-08
PL3181122T3 (pl) 2023-07-31
CN107115318A (zh) 2017-09-01
JP6351811B2 (ja) 2018-07-04
EP3181127A1 (en) 2017-06-21
MX2023008180A (es) 2023-08-03
US20160361313A1 (en) 2016-12-15
PL2802314T3 (pl) 2021-06-14
HRP20230510T1 (hr) 2023-10-27
FI3181128T3 (fi) 2023-06-02
AU2013208323B2 (en) 2017-07-06
US10772877B2 (en) 2020-09-15
US9833442B2 (en) 2017-12-05
AU2018200931B2 (en) 2019-07-18
IL293779B1 (en) 2023-05-01
US20210093616A1 (en) 2021-04-01
US20190275019A1 (en) 2019-09-12
CN107115317A (zh) 2017-09-01
AU2013208323A1 (en) 2014-07-24
US9833443B2 (en) 2017-12-05
US10314830B2 (en) 2019-06-11
JP2021073228A (ja) 2021-05-13
EP3181122A1 (en) 2017-06-21
JP6463417B2 (ja) 2019-02-06
US10561645B2 (en) 2020-02-18
EP2802314B1 (en) 2020-11-25
ES2946735T3 (es) 2023-07-25
IL293775A (en) 2022-08-01
US20140356443A1 (en) 2014-12-04
US9827230B2 (en) 2017-11-28
US10314829B2 (en) 2019-06-11
JP2015503612A (ja) 2015-02-02
AU2018200931A1 (en) 2018-03-01
EP3181128A1 (en) 2017-06-21
AU2018200928A1 (en) 2018-03-01
JP7391507B2 (ja) 2023-12-05
EP3766486A1 (en) 2021-01-20
EP3181122B1 (en) 2023-03-08
US11426391B2 (en) 2022-08-30
US20220160687A1 (en) 2022-05-26
US10561644B2 (en) 2020-02-18
US10143683B2 (en) 2018-12-04
AU2018200928B2 (en) 2019-07-18
US20190282553A1 (en) 2019-09-19
US11241419B2 (en) 2022-02-08
JP6463419B2 (ja) 2019-02-06
US20220296575A1 (en) 2022-09-22
US20180042906A1 (en) 2018-02-15
US10555937B2 (en) 2020-02-11
JP2017222694A (ja) 2017-12-21
US20190076413A1 (en) 2019-03-14
US20220168285A1 (en) 2022-06-02
IL233582B (en) 2021-09-30
IL293779A (en) 2022-08-01
CA2860932C (en) 2021-02-16
IL293775B2 (en) 2023-05-01
US20170143715A1 (en) 2017-05-25
US10561643B2 (en) 2020-02-18
IL293779B2 (en) 2023-09-01
JP2023123773A (ja) 2023-09-05
MX2022003458A (es) 2022-06-02
ES2946549T3 (es) 2023-07-20
JP6463418B2 (ja) 2019-02-06
IL293775B1 (en) 2023-01-01
AU2013208324A1 (en) 2014-07-24
US20160250153A1 (en) 2016-09-01
WO2013105895A1 (en) 2013-07-18
CN104159574A (zh) 2014-11-19
EP2802316A4 (en) 2015-11-18
AU2018200933A1 (en) 2018-03-01
US9456992B2 (en) 2016-10-04
US11376243B2 (en) 2022-07-05
JP2018012713A (ja) 2018-01-25
AU2021269331A1 (en) 2021-12-09
AU2019275513A1 (en) 2019-12-19
US20220117947A1 (en) 2022-04-21
JP2015503613A (ja) 2015-02-02
US20190255029A1 (en) 2019-08-22
US20200253941A1 (en) 2020-08-13
DK3181128T3 (da) 2023-06-06
FI3181122T3 (fi) 2023-05-31
IL233583B (en) 2020-10-29
JP6238310B2 (ja) 2017-11-29
JP2018012714A (ja) 2018-01-25
EP3181127B1 (en) 2023-03-08
MX347456B (es) 2017-04-27
MX2014008457A (es) 2015-02-12
JP2019070000A (ja) 2019-05-09
JP6351809B2 (ja) 2018-07-04
JP2017222695A (ja) 2017-12-21

Similar Documents

Publication Publication Date Title
US11517562B2 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: XSPRAY MICROPARTICLES AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRISANDER, MAGNUS;DEMIRBUKER, MUSTAFA;JESSON, GERALD;AND OTHERS;SIGNING DATES FROM 20140820 TO 20140905;REEL/FRAME:033930/0541

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION